AI and Machine Learning in IBD: Promising Applications and Remaining Challenges

Article Type
Changed
Wed, 06/05/2024 - 13:31
Display Headline
AI and Machine Learning in IBD: Promising Applications and Remaining Challenges
References
  1. Lewis JD, Parlett LE, Jonsson Funk ML, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165(5):1197-1205.e2. doi:10.1053/j.gastro.2023.07.003
  2. Sharma P. AI shows promise in diagnosis, treatment of IBD, but limitations, concerns remain. Healio. Published June 19, 2023. Accessed January 5, 2024. https://www.healio.com/news/gastroenterology/20230606/ai-shows-promise-in-diagnosis-treatment-of-ibd-but-limitations-concerns-remain
  3. Artificial intelligence (AI) vs. machine learning. Columbia Engineering.Accessed January 5, 2024. https://ai.engineering.columbia.edu/ai-vs-machine-learning/
  4. Zhang B, Shi H, Wang H. Machine learning and AI in cancer prognosis, prediction, and treatment selection: a critical approach. J Multidiscip Healthc. 2023;16:1779-1791. doi:10.2147/JMDH.S410301
  5. Cohen-Mekelburg S, Berry S, Stidham RW, Zhu J, Waljee AK. Clinical applications of artificial intelligence and machine learning-based methods in inflammatory bowel disease. J Gastroenterol Hepatol. 2021;36(2):279-285. doi:10.1111/jgh.15405
  6. Uche-Anya E, Anyane-Yeboa A, Berzin TM, Ghassemi M, May FP. Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity. Gut. 2022;71(9):1909-1915. doi:10.1136/gutjnl-2021-326271
  7. Stafford IS, Gosink MM, Mossotto E, Ennis S, Hauben M. A systematic review of artificial intelligence and machine learning applications to inflammatory bowel disease, with practical guidelines for interpretation. Inflamm Bowel Dis. 2022;28(10):1573-1583. doi:10.1093/ibd/izac115
  8. Gubatan J, Levitte S, Patel A, Balabanis T, Wei MT, Sinha SR. Artificial intelligence applications in inflammatory bowel disease: emerging technologies and future directions. World J Gastroenterol. 2021;27(17):1920-1935. doi:10.3748/wjg.v27.i17.1920
Author and Disclosure Information

Shirley Cohen-Mekelburg, MD, MS
Assistant Professor
Division of Gastroenterology
Michigan Medicine
Director of IBD
VA Ann Arbor Health Care System
Ann Arbor, Michigan

Dr. Cohen-Mekelburg has disclosed no relevant financial relationships.

Publications
Topics
Author and Disclosure Information

Shirley Cohen-Mekelburg, MD, MS
Assistant Professor
Division of Gastroenterology
Michigan Medicine
Director of IBD
VA Ann Arbor Health Care System
Ann Arbor, Michigan

Dr. Cohen-Mekelburg has disclosed no relevant financial relationships.

Author and Disclosure Information

Shirley Cohen-Mekelburg, MD, MS
Assistant Professor
Division of Gastroenterology
Michigan Medicine
Director of IBD
VA Ann Arbor Health Care System
Ann Arbor, Michigan

Dr. Cohen-Mekelburg has disclosed no relevant financial relationships.

References
  1. Lewis JD, Parlett LE, Jonsson Funk ML, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165(5):1197-1205.e2. doi:10.1053/j.gastro.2023.07.003
  2. Sharma P. AI shows promise in diagnosis, treatment of IBD, but limitations, concerns remain. Healio. Published June 19, 2023. Accessed January 5, 2024. https://www.healio.com/news/gastroenterology/20230606/ai-shows-promise-in-diagnosis-treatment-of-ibd-but-limitations-concerns-remain
  3. Artificial intelligence (AI) vs. machine learning. Columbia Engineering.Accessed January 5, 2024. https://ai.engineering.columbia.edu/ai-vs-machine-learning/
  4. Zhang B, Shi H, Wang H. Machine learning and AI in cancer prognosis, prediction, and treatment selection: a critical approach. J Multidiscip Healthc. 2023;16:1779-1791. doi:10.2147/JMDH.S410301
  5. Cohen-Mekelburg S, Berry S, Stidham RW, Zhu J, Waljee AK. Clinical applications of artificial intelligence and machine learning-based methods in inflammatory bowel disease. J Gastroenterol Hepatol. 2021;36(2):279-285. doi:10.1111/jgh.15405
  6. Uche-Anya E, Anyane-Yeboa A, Berzin TM, Ghassemi M, May FP. Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity. Gut. 2022;71(9):1909-1915. doi:10.1136/gutjnl-2021-326271
  7. Stafford IS, Gosink MM, Mossotto E, Ennis S, Hauben M. A systematic review of artificial intelligence and machine learning applications to inflammatory bowel disease, with practical guidelines for interpretation. Inflamm Bowel Dis. 2022;28(10):1573-1583. doi:10.1093/ibd/izac115
  8. Gubatan J, Levitte S, Patel A, Balabanis T, Wei MT, Sinha SR. Artificial intelligence applications in inflammatory bowel disease: emerging technologies and future directions. World J Gastroenterol. 2021;27(17):1920-1935. doi:10.3748/wjg.v27.i17.1920
References
  1. Lewis JD, Parlett LE, Jonsson Funk ML, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165(5):1197-1205.e2. doi:10.1053/j.gastro.2023.07.003
  2. Sharma P. AI shows promise in diagnosis, treatment of IBD, but limitations, concerns remain. Healio. Published June 19, 2023. Accessed January 5, 2024. https://www.healio.com/news/gastroenterology/20230606/ai-shows-promise-in-diagnosis-treatment-of-ibd-but-limitations-concerns-remain
  3. Artificial intelligence (AI) vs. machine learning. Columbia Engineering.Accessed January 5, 2024. https://ai.engineering.columbia.edu/ai-vs-machine-learning/
  4. Zhang B, Shi H, Wang H. Machine learning and AI in cancer prognosis, prediction, and treatment selection: a critical approach. J Multidiscip Healthc. 2023;16:1779-1791. doi:10.2147/JMDH.S410301
  5. Cohen-Mekelburg S, Berry S, Stidham RW, Zhu J, Waljee AK. Clinical applications of artificial intelligence and machine learning-based methods in inflammatory bowel disease. J Gastroenterol Hepatol. 2021;36(2):279-285. doi:10.1111/jgh.15405
  6. Uche-Anya E, Anyane-Yeboa A, Berzin TM, Ghassemi M, May FP. Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity. Gut. 2022;71(9):1909-1915. doi:10.1136/gutjnl-2021-326271
  7. Stafford IS, Gosink MM, Mossotto E, Ennis S, Hauben M. A systematic review of artificial intelligence and machine learning applications to inflammatory bowel disease, with practical guidelines for interpretation. Inflamm Bowel Dis. 2022;28(10):1573-1583. doi:10.1093/ibd/izac115
  8. Gubatan J, Levitte S, Patel A, Balabanis T, Wei MT, Sinha SR. Artificial intelligence applications in inflammatory bowel disease: emerging technologies and future directions. World J Gastroenterol. 2021;27(17):1920-1935. doi:10.3748/wjg.v27.i17.1920
Publications
Publications
Topics
Article Type
Display Headline
AI and Machine Learning in IBD: Promising Applications and Remaining Challenges
Display Headline
AI and Machine Learning in IBD: Promising Applications and Remaining Challenges
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Thu, 05/30/2024 - 13:00
Un-Gate On Date
Thu, 05/30/2024 - 13:00
Use ProPublica
CFC Schedule Remove Status
Thu, 05/30/2024 - 13:00
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Nearly 1 in 100 Americans have Inflammatory Bowel Disease (IBD), with up to 56,000 new cases being diagnosed each year.IBD is a complex disease with a myriad of presentations, possible treatment approaches, and patient outcomes. Artificial intelligence (AI)—a field of technology which began in the 1950s—refers to the ability of computers to learn and perform tasks that would have typically required human intelligence, while “machine learning” refers to the development of the algorithms that help AI learn patterns from data.2,3 The goal in many industries, including health care, is for AI to aid in and improve decision-making. Applications of AI including machine learning already greatly influence the oncology space, aiding in risk assessment, early diagnosis, prognosis, and treatment decision-making.4 Similar utilizations are being investigated to help improve the quality and efficiency of care for patients with IBD, but there is still much research to be done before we can fully leverage such tools in everyday practice.5

Although extensive progress in AI has been made since the turn of the century, several limitations remain. Poor-quality data sets may lead to inaccurate predictions, and it is difficult to generalize data sets to minority populations. In health care, clinicians must also understand and be able to interpret the algorithms in order to trust and apply them in practice. Lastly, and importantly, there are ethical concerns regarding patient privacy in data collection.6

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media

Simulation-Based Training in Endoscopy: Benefits and Challenges

Article Type
Changed
Wed, 06/05/2024 - 13:39
Display Headline
Simulation-Based Training in Endoscopy: Benefits and Challenges
References
  1. Hayden EM, Khatri A, Kelly HR, Yager PH, Salazar GM. Mannequinbased telesimulation: increasing access to simulation-based education. Acad Emerg Med. 2018;25(2):144-147. doi:10.1111/acem.13299
  2. Khan R, Scaffidi MA, Grover SC, Gimpaya N, Walsh CM. Simulation in endoscopy: practical educational strategies to improve learning. World J Gastrointest Endosc. 2019;11(3):209-218. doi:10.4253/wjge.v11.i3.209
  3. Bhushan S, Anandasabapathy S, Shukla R. Use of augmented reality and virtual reality technologies in endoscopic training. Clin Gastroenterol Hepatol. 2018;16(11):1688-1691. doi:10.1016/j.cgh.2018.08.021
  4. Bienstock J, Heuer A. A review on the evolution of simulationbased training to help build a safer future. Medicine (Baltimore). 2022;101(25):e29503. doi:10.1097/MD.0000000000029503
  5. Emergen Research. Global augmented and virtual reality in healthcare market size to reach USD 20.76 billion in 2032. GlobeNewswire. Published October 12, 2023. Accessed January 5, 2024. https://www.globenewswire.com/news-release/2023/10/12/2759433/0/en/GlobalAugmented-and-Virtual-Reality-in-Healthcare-Market-Size-to-ReachUSD-20-76-Billion-in-2032-Emergen-Research.html
  6. Hippe DS, Umoren RA, McGee A, Bucher SL, Bresnahan BW. A targeted systematic review of cost analyses for implementation of simulation-based education in healthcare. SAGE Open Med. 2020;8:2050312120913451. doi:10.1177/2050312120913451
Author and Disclosure Information

Richa Shukla, MD
Assistant Professor
Margaret M. and Albert B. Alkek Department of Medicine
Section of Gastroenterology and Hepatology
Baylor College of Medicine
Houston, Texas

Disclosures:
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie
Received income in an amount equal to or greater than $250 from: AbbVie

Publications
Topics
Author and Disclosure Information

Richa Shukla, MD
Assistant Professor
Margaret M. and Albert B. Alkek Department of Medicine
Section of Gastroenterology and Hepatology
Baylor College of Medicine
Houston, Texas

Disclosures:
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie
Received income in an amount equal to or greater than $250 from: AbbVie

Author and Disclosure Information

Richa Shukla, MD
Assistant Professor
Margaret M. and Albert B. Alkek Department of Medicine
Section of Gastroenterology and Hepatology
Baylor College of Medicine
Houston, Texas

Disclosures:
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie
Received income in an amount equal to or greater than $250 from: AbbVie

References
  1. Hayden EM, Khatri A, Kelly HR, Yager PH, Salazar GM. Mannequinbased telesimulation: increasing access to simulation-based education. Acad Emerg Med. 2018;25(2):144-147. doi:10.1111/acem.13299
  2. Khan R, Scaffidi MA, Grover SC, Gimpaya N, Walsh CM. Simulation in endoscopy: practical educational strategies to improve learning. World J Gastrointest Endosc. 2019;11(3):209-218. doi:10.4253/wjge.v11.i3.209
  3. Bhushan S, Anandasabapathy S, Shukla R. Use of augmented reality and virtual reality technologies in endoscopic training. Clin Gastroenterol Hepatol. 2018;16(11):1688-1691. doi:10.1016/j.cgh.2018.08.021
  4. Bienstock J, Heuer A. A review on the evolution of simulationbased training to help build a safer future. Medicine (Baltimore). 2022;101(25):e29503. doi:10.1097/MD.0000000000029503
  5. Emergen Research. Global augmented and virtual reality in healthcare market size to reach USD 20.76 billion in 2032. GlobeNewswire. Published October 12, 2023. Accessed January 5, 2024. https://www.globenewswire.com/news-release/2023/10/12/2759433/0/en/GlobalAugmented-and-Virtual-Reality-in-Healthcare-Market-Size-to-ReachUSD-20-76-Billion-in-2032-Emergen-Research.html
  6. Hippe DS, Umoren RA, McGee A, Bucher SL, Bresnahan BW. A targeted systematic review of cost analyses for implementation of simulation-based education in healthcare. SAGE Open Med. 2020;8:2050312120913451. doi:10.1177/2050312120913451
References
  1. Hayden EM, Khatri A, Kelly HR, Yager PH, Salazar GM. Mannequinbased telesimulation: increasing access to simulation-based education. Acad Emerg Med. 2018;25(2):144-147. doi:10.1111/acem.13299
  2. Khan R, Scaffidi MA, Grover SC, Gimpaya N, Walsh CM. Simulation in endoscopy: practical educational strategies to improve learning. World J Gastrointest Endosc. 2019;11(3):209-218. doi:10.4253/wjge.v11.i3.209
  3. Bhushan S, Anandasabapathy S, Shukla R. Use of augmented reality and virtual reality technologies in endoscopic training. Clin Gastroenterol Hepatol. 2018;16(11):1688-1691. doi:10.1016/j.cgh.2018.08.021
  4. Bienstock J, Heuer A. A review on the evolution of simulationbased training to help build a safer future. Medicine (Baltimore). 2022;101(25):e29503. doi:10.1097/MD.0000000000029503
  5. Emergen Research. Global augmented and virtual reality in healthcare market size to reach USD 20.76 billion in 2032. GlobeNewswire. Published October 12, 2023. Accessed January 5, 2024. https://www.globenewswire.com/news-release/2023/10/12/2759433/0/en/GlobalAugmented-and-Virtual-Reality-in-Healthcare-Market-Size-to-ReachUSD-20-76-Billion-in-2032-Emergen-Research.html
  6. Hippe DS, Umoren RA, McGee A, Bucher SL, Bresnahan BW. A targeted systematic review of cost analyses for implementation of simulation-based education in healthcare. SAGE Open Med. 2020;8:2050312120913451. doi:10.1177/2050312120913451
Publications
Publications
Topics
Article Type
Display Headline
Simulation-Based Training in Endoscopy: Benefits and Challenges
Display Headline
Simulation-Based Training in Endoscopy: Benefits and Challenges
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Thu, 05/30/2024 - 12:15
Un-Gate On Date
Thu, 05/30/2024 - 12:15
Use ProPublica
CFC Schedule Remove Status
Thu, 05/30/2024 - 12:15
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

The way methodologies used to train medical students and professionals are constantly evolving; centuries of studying anatomy with models and figurines—and then practicing on real patients—are now being reexamined in light of emerging technology. Simulation-based training offers a new, seemingly “riskfree” approach to learning because trainees can practice procedures in safe, realistic, patient-free environments. Early mistakes can be made with minimal consequence, training can be tailored to include highly specific clinical scenarios, and the evolving technology helps us accomplish these goals in xtremely realistic simulations.1-3 The COVID-19 pandemic further escalated the need for advanced training to be available virtually and helped to shape what these types of programs should look like moving forward.4

As with every new piece of technology, some limitations still need to be addressed. Cost is the first one that comes to mind; while the long-term cost vs benefit debate is not yet settled, the upfront expense is substantial and immediately makes simulationbased training less accessible. The good news is that subsequent costs, such as those for software updates and upgrades, may be much lower. We are also at the mercy of possible technical issues and malfunctions, and the transferability of skills learned virtually into real-life practice may vary from person to person. Nevertheless, many promising elements make simulation-based training an exciting development for training the next generation of endoscopists.

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media

The Changing Face of IBD: Beyond the Western World

Article Type
Changed
Wed, 06/05/2024 - 12:53
Display Headline
The Changing Face of IBD: Beyond the Western World
References
  1. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56-66. doi:10.1038/s41575-020-00360-x
  2. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease [published correction appears in Gastroenterology. 2017;152(8):2084]. Gastroenterology. 2017;152(2):313-321.e2. doi:10.1053/j.gastro.2016.10.020
  3. Balderramo D, Quaresma AB, Olivera PA, et al. Challenges in diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024; 9(3):263-272. doi:10.1016/S2468-1253(23)00284-4
  4. Song EM, Na SY, Hong SN, Ng SC, Hisamatsu T, Ye BD. Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting. Intest Res. 2023;21(3):339-352. doi:10.5217/ir.2022.00135
  5. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17-30. doi:10.1016/S2468-1253(19)30333-4
  6. Chen X, Xiang X, Xia W, et al. Evolving trends and burden of inflammatory bowel disease in Asia, 1990-2019: a comprehensive analysis based on the Global Burden of Disease Study. J Epidemiol Glob Health. 2023;13(4):725-739. doi:10.1007/s44197-023-00145-w
  7. Zhao M, Feng R, Ben-Horin S, et al. Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Aliment Pharmacol Ther. 2022;55(3):266-276. doi:10.1111/apt.16703
  8. Lewis JD, Parlett LE, Jonsson Funk ML, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165(5):1197-1205.e2. doi:10.1053/j.gastro.2023.07.003
  9. Quaresma AB, Damiao AOMC, Coy CSR, et al. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: a large population-based study. Lancet Reg Health Am. 2022;13:100298. doi:10.1016/j.lana.2022.100298
  10. Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1-37. doi:10.1093/ecco-jcc/jjad108
  11. Coward S, Benchimol EI, Bernstein CN, et al; Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC). Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian Nationwide Analysis. Am J Gastroenterol. 2024 Mar 18. doi:10.14309/ajg.0000000000002687. Epub ahead of print. PMID: 38299598.
  12. Dorn-Rasmussen M, Lo B, Zhao M, Kaplan GG, Malham M, Wewer V, Burisch J. The Incidence and Prevalence of Paediatric- and Adult-Onset Inflammatory Bowel Disease in Denmark During a 37-Year Period: A Nationwide Cohort Study (1980-2017). J Crohns Colitis. 2023;17(2):259- 268. doi:10.1093/ecco-jcc/jjac138. PMID: 36125076.
  13. Watermeyer G, Katsidzira L, Setshedi M, et al. Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis. Lancet Gastroenterol Hepatol. 2022;7(10):952-961. doi:10.1016/S2468-1253(22)00047-4
  14. Stulman MY, Asayag N, Focht G, et al. Epidemiology of Inflammatory Bowel Diseases in Israel: A Nationwide Epi-Israeli IBD Research Nucleus Study. Inflamm Bowel Dis. 2021;27(11):1784-1794. doi:10.1093/ibd/izaa341
  15. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies [published correction appears in Lancet. 2020;396(10256):e56]. Lancet. 2017;390(10114):2769-2778. doi:10.1016/S0140-6736(17)32448-0
  16. Busingye D, Pollack A, Chidwick K. Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study. PLoS One. 2021;16(5):e0252458. Published 2021 May 27. doi:10.1371/ journal.pone.0252458
  17. Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol. 2018;3(9):644-653. doi:10.1016/S2468-1253(18)30159-6
  18. Inflammatory bowel disease (IBD): comorbidities. Centers for Disease Control and Prevention. Last reviewed April 14, 2022. Accessed February 21, 2024. https://www.cdc.gov/ibd/data-and-statistics/comorbidities.html
  19. Mosli MH, Alsahafi M, Alsanea MN, Alhasani F, Ahmed M, Saadah O. Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study. BMC Gastroenterol. 2022;22(1):487. doi:10.1186/s12876-022-02578-2
  20. Inflammatory bowel disease (IBD). Mayo Clinic. September 3, 2022. Accessed February 21, 2024. https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/diagnosis-treatment/drc-20353320
  21. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and Colitis Epidemiology Study. Gastroenterology. 2013;145(1):158-165.e2. doi:10.1053/j.gastro.2013.04.007
  22. Ng SC, Tsoi KK, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18(6):1164-1176. doi:10.1002/ibd.21845
  23. Banerjee R, Pal P, Mak JWY, Ng SC. Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol. 2020;5(12):1076-1088. doi:10.1016/S2468-1253(20)30299-5
  24. Ng SC, Mak JWY, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol. 2020;5(12):1089-1100. 10.1016/S2468-1253(20)30298-3
  25. Ng SC. Emerging trends of inflammatory bowel disease in Asia. Gastroenterol Hepatol (N Y). 2016;12(3):193-196. PMID: 27231449
  26. Ran Z, Wu K, Matsuoka K, et al. Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol. 2021;36(3):637-645. doi:10.1111/jgh.15185
  27. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979-986. doi:10.1038/ng.3359
  28. Yamamoto-Furusho JK, Parra-Holguín NN, Juliao-Baños F, et al; for the EPILATAM study group. Clinical differentiation of inflammatory bowel disease (IBD) in Latin America and the Caribbean. Medicine (Baltimore). 2022;101(3):e28624. doi:10.1097/MD.0000000000028624
Author and Disclosure Information

Gilaad G. Kaplan, MD, MPH, AGAF
Professor
Gastroenterologist
Department of Medicine
University of Calgary
Alberta, Canada

Disclosures:
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Janssen; Pfizer
Received research grant from: Ferring

Paulo Kotze, MD, MS, PhD
Professor
Cajuru University Hospital
Curitiba, Puerto Rico

Disclosures:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Pfizer; Janssen; Takeda

Siew Chien Ng, MBBS, PhD, AGAF
Professor, Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Professor, Department of Medicine and Therapeutics
Division of Gastroenterology and Hepatology
Prince of Wales Hospital
Hong Kong

Disclosures:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: The Chinese University of Hong Kong; GenieBiome Limited
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Ferring; Janssen;
Menarini; Takeda; Tillotts; Pfizer
Received research grant from: AbbVie; Ferring; Olympus; Janssen
Have a 5% or greater equity interest in: GenieBiome Limited
Received income in an amount equal to or greater than $250 from: The Chinese
University of Hong Kong; GenieBiome Limited

Publications
Topics
Author and Disclosure Information

Gilaad G. Kaplan, MD, MPH, AGAF
Professor
Gastroenterologist
Department of Medicine
University of Calgary
Alberta, Canada

Disclosures:
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Janssen; Pfizer
Received research grant from: Ferring

Paulo Kotze, MD, MS, PhD
Professor
Cajuru University Hospital
Curitiba, Puerto Rico

Disclosures:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Pfizer; Janssen; Takeda

Siew Chien Ng, MBBS, PhD, AGAF
Professor, Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Professor, Department of Medicine and Therapeutics
Division of Gastroenterology and Hepatology
Prince of Wales Hospital
Hong Kong

Disclosures:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: The Chinese University of Hong Kong; GenieBiome Limited
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Ferring; Janssen;
Menarini; Takeda; Tillotts; Pfizer
Received research grant from: AbbVie; Ferring; Olympus; Janssen
Have a 5% or greater equity interest in: GenieBiome Limited
Received income in an amount equal to or greater than $250 from: The Chinese
University of Hong Kong; GenieBiome Limited

Author and Disclosure Information

Gilaad G. Kaplan, MD, MPH, AGAF
Professor
Gastroenterologist
Department of Medicine
University of Calgary
Alberta, Canada

Disclosures:
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Janssen; Pfizer
Received research grant from: Ferring

Paulo Kotze, MD, MS, PhD
Professor
Cajuru University Hospital
Curitiba, Puerto Rico

Disclosures:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Pfizer; Janssen; Takeda

Siew Chien Ng, MBBS, PhD, AGAF
Professor, Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Professor, Department of Medicine and Therapeutics
Division of Gastroenterology and Hepatology
Prince of Wales Hospital
Hong Kong

Disclosures:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: The Chinese University of Hong Kong; GenieBiome Limited
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Ferring; Janssen;
Menarini; Takeda; Tillotts; Pfizer
Received research grant from: AbbVie; Ferring; Olympus; Janssen
Have a 5% or greater equity interest in: GenieBiome Limited
Received income in an amount equal to or greater than $250 from: The Chinese
University of Hong Kong; GenieBiome Limited

References
  1. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56-66. doi:10.1038/s41575-020-00360-x
  2. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease [published correction appears in Gastroenterology. 2017;152(8):2084]. Gastroenterology. 2017;152(2):313-321.e2. doi:10.1053/j.gastro.2016.10.020
  3. Balderramo D, Quaresma AB, Olivera PA, et al. Challenges in diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024; 9(3):263-272. doi:10.1016/S2468-1253(23)00284-4
  4. Song EM, Na SY, Hong SN, Ng SC, Hisamatsu T, Ye BD. Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting. Intest Res. 2023;21(3):339-352. doi:10.5217/ir.2022.00135
  5. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17-30. doi:10.1016/S2468-1253(19)30333-4
  6. Chen X, Xiang X, Xia W, et al. Evolving trends and burden of inflammatory bowel disease in Asia, 1990-2019: a comprehensive analysis based on the Global Burden of Disease Study. J Epidemiol Glob Health. 2023;13(4):725-739. doi:10.1007/s44197-023-00145-w
  7. Zhao M, Feng R, Ben-Horin S, et al. Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Aliment Pharmacol Ther. 2022;55(3):266-276. doi:10.1111/apt.16703
  8. Lewis JD, Parlett LE, Jonsson Funk ML, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165(5):1197-1205.e2. doi:10.1053/j.gastro.2023.07.003
  9. Quaresma AB, Damiao AOMC, Coy CSR, et al. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: a large population-based study. Lancet Reg Health Am. 2022;13:100298. doi:10.1016/j.lana.2022.100298
  10. Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1-37. doi:10.1093/ecco-jcc/jjad108
  11. Coward S, Benchimol EI, Bernstein CN, et al; Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC). Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian Nationwide Analysis. Am J Gastroenterol. 2024 Mar 18. doi:10.14309/ajg.0000000000002687. Epub ahead of print. PMID: 38299598.
  12. Dorn-Rasmussen M, Lo B, Zhao M, Kaplan GG, Malham M, Wewer V, Burisch J. The Incidence and Prevalence of Paediatric- and Adult-Onset Inflammatory Bowel Disease in Denmark During a 37-Year Period: A Nationwide Cohort Study (1980-2017). J Crohns Colitis. 2023;17(2):259- 268. doi:10.1093/ecco-jcc/jjac138. PMID: 36125076.
  13. Watermeyer G, Katsidzira L, Setshedi M, et al. Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis. Lancet Gastroenterol Hepatol. 2022;7(10):952-961. doi:10.1016/S2468-1253(22)00047-4
  14. Stulman MY, Asayag N, Focht G, et al. Epidemiology of Inflammatory Bowel Diseases in Israel: A Nationwide Epi-Israeli IBD Research Nucleus Study. Inflamm Bowel Dis. 2021;27(11):1784-1794. doi:10.1093/ibd/izaa341
  15. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies [published correction appears in Lancet. 2020;396(10256):e56]. Lancet. 2017;390(10114):2769-2778. doi:10.1016/S0140-6736(17)32448-0
  16. Busingye D, Pollack A, Chidwick K. Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study. PLoS One. 2021;16(5):e0252458. Published 2021 May 27. doi:10.1371/ journal.pone.0252458
  17. Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol. 2018;3(9):644-653. doi:10.1016/S2468-1253(18)30159-6
  18. Inflammatory bowel disease (IBD): comorbidities. Centers for Disease Control and Prevention. Last reviewed April 14, 2022. Accessed February 21, 2024. https://www.cdc.gov/ibd/data-and-statistics/comorbidities.html
  19. Mosli MH, Alsahafi M, Alsanea MN, Alhasani F, Ahmed M, Saadah O. Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study. BMC Gastroenterol. 2022;22(1):487. doi:10.1186/s12876-022-02578-2
  20. Inflammatory bowel disease (IBD). Mayo Clinic. September 3, 2022. Accessed February 21, 2024. https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/diagnosis-treatment/drc-20353320
  21. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and Colitis Epidemiology Study. Gastroenterology. 2013;145(1):158-165.e2. doi:10.1053/j.gastro.2013.04.007
  22. Ng SC, Tsoi KK, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18(6):1164-1176. doi:10.1002/ibd.21845
  23. Banerjee R, Pal P, Mak JWY, Ng SC. Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol. 2020;5(12):1076-1088. doi:10.1016/S2468-1253(20)30299-5
  24. Ng SC, Mak JWY, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol. 2020;5(12):1089-1100. 10.1016/S2468-1253(20)30298-3
  25. Ng SC. Emerging trends of inflammatory bowel disease in Asia. Gastroenterol Hepatol (N Y). 2016;12(3):193-196. PMID: 27231449
  26. Ran Z, Wu K, Matsuoka K, et al. Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol. 2021;36(3):637-645. doi:10.1111/jgh.15185
  27. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979-986. doi:10.1038/ng.3359
  28. Yamamoto-Furusho JK, Parra-Holguín NN, Juliao-Baños F, et al; for the EPILATAM study group. Clinical differentiation of inflammatory bowel disease (IBD) in Latin America and the Caribbean. Medicine (Baltimore). 2022;101(3):e28624. doi:10.1097/MD.0000000000028624
References
  1. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56-66. doi:10.1038/s41575-020-00360-x
  2. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease [published correction appears in Gastroenterology. 2017;152(8):2084]. Gastroenterology. 2017;152(2):313-321.e2. doi:10.1053/j.gastro.2016.10.020
  3. Balderramo D, Quaresma AB, Olivera PA, et al. Challenges in diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024; 9(3):263-272. doi:10.1016/S2468-1253(23)00284-4
  4. Song EM, Na SY, Hong SN, Ng SC, Hisamatsu T, Ye BD. Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting. Intest Res. 2023;21(3):339-352. doi:10.5217/ir.2022.00135
  5. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17-30. doi:10.1016/S2468-1253(19)30333-4
  6. Chen X, Xiang X, Xia W, et al. Evolving trends and burden of inflammatory bowel disease in Asia, 1990-2019: a comprehensive analysis based on the Global Burden of Disease Study. J Epidemiol Glob Health. 2023;13(4):725-739. doi:10.1007/s44197-023-00145-w
  7. Zhao M, Feng R, Ben-Horin S, et al. Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Aliment Pharmacol Ther. 2022;55(3):266-276. doi:10.1111/apt.16703
  8. Lewis JD, Parlett LE, Jonsson Funk ML, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165(5):1197-1205.e2. doi:10.1053/j.gastro.2023.07.003
  9. Quaresma AB, Damiao AOMC, Coy CSR, et al. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: a large population-based study. Lancet Reg Health Am. 2022;13:100298. doi:10.1016/j.lana.2022.100298
  10. Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1-37. doi:10.1093/ecco-jcc/jjad108
  11. Coward S, Benchimol EI, Bernstein CN, et al; Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC). Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian Nationwide Analysis. Am J Gastroenterol. 2024 Mar 18. doi:10.14309/ajg.0000000000002687. Epub ahead of print. PMID: 38299598.
  12. Dorn-Rasmussen M, Lo B, Zhao M, Kaplan GG, Malham M, Wewer V, Burisch J. The Incidence and Prevalence of Paediatric- and Adult-Onset Inflammatory Bowel Disease in Denmark During a 37-Year Period: A Nationwide Cohort Study (1980-2017). J Crohns Colitis. 2023;17(2):259- 268. doi:10.1093/ecco-jcc/jjac138. PMID: 36125076.
  13. Watermeyer G, Katsidzira L, Setshedi M, et al. Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis. Lancet Gastroenterol Hepatol. 2022;7(10):952-961. doi:10.1016/S2468-1253(22)00047-4
  14. Stulman MY, Asayag N, Focht G, et al. Epidemiology of Inflammatory Bowel Diseases in Israel: A Nationwide Epi-Israeli IBD Research Nucleus Study. Inflamm Bowel Dis. 2021;27(11):1784-1794. doi:10.1093/ibd/izaa341
  15. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies [published correction appears in Lancet. 2020;396(10256):e56]. Lancet. 2017;390(10114):2769-2778. doi:10.1016/S0140-6736(17)32448-0
  16. Busingye D, Pollack A, Chidwick K. Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study. PLoS One. 2021;16(5):e0252458. Published 2021 May 27. doi:10.1371/ journal.pone.0252458
  17. Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol. 2018;3(9):644-653. doi:10.1016/S2468-1253(18)30159-6
  18. Inflammatory bowel disease (IBD): comorbidities. Centers for Disease Control and Prevention. Last reviewed April 14, 2022. Accessed February 21, 2024. https://www.cdc.gov/ibd/data-and-statistics/comorbidities.html
  19. Mosli MH, Alsahafi M, Alsanea MN, Alhasani F, Ahmed M, Saadah O. Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study. BMC Gastroenterol. 2022;22(1):487. doi:10.1186/s12876-022-02578-2
  20. Inflammatory bowel disease (IBD). Mayo Clinic. September 3, 2022. Accessed February 21, 2024. https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/diagnosis-treatment/drc-20353320
  21. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and Colitis Epidemiology Study. Gastroenterology. 2013;145(1):158-165.e2. doi:10.1053/j.gastro.2013.04.007
  22. Ng SC, Tsoi KK, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18(6):1164-1176. doi:10.1002/ibd.21845
  23. Banerjee R, Pal P, Mak JWY, Ng SC. Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol. 2020;5(12):1076-1088. doi:10.1016/S2468-1253(20)30299-5
  24. Ng SC, Mak JWY, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol. 2020;5(12):1089-1100. 10.1016/S2468-1253(20)30298-3
  25. Ng SC. Emerging trends of inflammatory bowel disease in Asia. Gastroenterol Hepatol (N Y). 2016;12(3):193-196. PMID: 27231449
  26. Ran Z, Wu K, Matsuoka K, et al. Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol. 2021;36(3):637-645. doi:10.1111/jgh.15185
  27. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979-986. doi:10.1038/ng.3359
  28. Yamamoto-Furusho JK, Parra-Holguín NN, Juliao-Baños F, et al; for the EPILATAM study group. Clinical differentiation of inflammatory bowel disease (IBD) in Latin America and the Caribbean. Medicine (Baltimore). 2022;101(3):e28624. doi:10.1097/MD.0000000000028624
Publications
Publications
Topics
Article Type
Display Headline
The Changing Face of IBD: Beyond the Western World
Display Headline
The Changing Face of IBD: Beyond the Western World
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 05/28/2024 - 12:00
Un-Gate On Date
Tue, 05/28/2024 - 12:00
Use ProPublica
CFC Schedule Remove Status
Tue, 05/28/2024 - 12:00
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Inflammatory bowel disease (IBD) has become a global disease, with rising incidence in non-Western cohorts such as Asia and Latin America.1 These newly industrialized countries are in an “acceleration in incidence” stage, while Western countries are in a “compounding prevalence” stage as new cases level out, but prevalence climbs steadily.1 Incidence is varied throughout Asia and remains comparatively lower than in Western countries; this discrepancy is influenced by environmental risk factors such as diets high in fat, animal protein, sugar, fast food, and food additives, which are common in the Western world.2 In Latin America and the Caribbean, the incidence of IBD is also increasing, but is still less than in Western countries, and variance between countries depends on the level of urbanization and industrialization.3 Risk factors are like those of Asia, and also include inadequate living conditions, the absence of exposure to infectious diseases, treated water, and a limited ability to differentiate the diagnosis of infectious diseases, representing a key difference compared with the Western world.3 Treatment within these groups seems to be similarly effective compared with the Western world, although some areas of Asia and Latin America face more barriers to accessing healthcare, which is a key area that global health care could target.3,4

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media

Role of Non-invasive Biomarkers in the Evaluation and Management of MASLD

Article Type
Changed
Wed, 06/05/2024 - 12:58
Display Headline
Role of Non-invasive Biomarkers in the Evaluation and Management of MASLD
References
  1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520

  2. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2023;165(4):1080-1088. doi:10.1053/j.gastro.2023.06.013

  3. Di Mauro S, Scamporrino A, Filippello A, et al. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. Int J Mol Sci. 2021;22(21):11905. Published 2021 Nov 2. doi:10.3390/ijms222111905

  4. Hsu C, Caussy C, Imajo K, et al. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin Gastroenterol Hepatol. 2019;17(4):630-637.e8. doi:10.1016/j.cgh.2018.05.059

  5. Ilagan-Ying YC, Banini BA, Do A, Lam R, Lim JK. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Curr Gastroenterol Rep. 2023;25(10):213-224. doi:10.1007/s11894-023-00883-8

  6. Chen W, Gao Y, Xie W, et al. Genome-wide association analyses provide genetic and biochemical insights into natural variation in rice metabolism. Nat Genet. 2014;46(7):714-721. doi:10.1038/ng.3007

  7. Wu YL, Kumar R, Wang MF, et al. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol. 2021;27(34):5753-5763. doi:10.3748/wjg.v27.i34.5753

  8. Kaneva AM, Bojko ER. Fatty liver index (FLI): more than a marker of hepatic steatosis. J Physiol Biochem. Published online October 25, 2023. doi:10.1007/s13105-023-00991-z

Author and Disclosure Information

Julia J. Wattacheril, MD, MPH
Associate Professor
Department of Medicine
Director, MASLD Program
Division of Digestive and Liver Disease
Center for Liver Disease and Transplantation
Columbia University Irving Medical Center
New York Presbyterian Hospital
New York, New York

Disclosures:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for:
AlphaSights, GlaxoSmithKline
Received research grant from: Galectin Therapeutics; Intercept Pharmaceuticals; AMRA Medical

Publications
Topics
Author and Disclosure Information

Julia J. Wattacheril, MD, MPH
Associate Professor
Department of Medicine
Director, MASLD Program
Division of Digestive and Liver Disease
Center for Liver Disease and Transplantation
Columbia University Irving Medical Center
New York Presbyterian Hospital
New York, New York

Disclosures:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for:
AlphaSights, GlaxoSmithKline
Received research grant from: Galectin Therapeutics; Intercept Pharmaceuticals; AMRA Medical

Author and Disclosure Information

Julia J. Wattacheril, MD, MPH
Associate Professor
Department of Medicine
Director, MASLD Program
Division of Digestive and Liver Disease
Center for Liver Disease and Transplantation
Columbia University Irving Medical Center
New York Presbyterian Hospital
New York, New York

Disclosures:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for:
AlphaSights, GlaxoSmithKline
Received research grant from: Galectin Therapeutics; Intercept Pharmaceuticals; AMRA Medical

References
  1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520

  2. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2023;165(4):1080-1088. doi:10.1053/j.gastro.2023.06.013

  3. Di Mauro S, Scamporrino A, Filippello A, et al. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. Int J Mol Sci. 2021;22(21):11905. Published 2021 Nov 2. doi:10.3390/ijms222111905

  4. Hsu C, Caussy C, Imajo K, et al. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin Gastroenterol Hepatol. 2019;17(4):630-637.e8. doi:10.1016/j.cgh.2018.05.059

  5. Ilagan-Ying YC, Banini BA, Do A, Lam R, Lim JK. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Curr Gastroenterol Rep. 2023;25(10):213-224. doi:10.1007/s11894-023-00883-8

  6. Chen W, Gao Y, Xie W, et al. Genome-wide association analyses provide genetic and biochemical insights into natural variation in rice metabolism. Nat Genet. 2014;46(7):714-721. doi:10.1038/ng.3007

  7. Wu YL, Kumar R, Wang MF, et al. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol. 2021;27(34):5753-5763. doi:10.3748/wjg.v27.i34.5753

  8. Kaneva AM, Bojko ER. Fatty liver index (FLI): more than a marker of hepatic steatosis. J Physiol Biochem. Published online October 25, 2023. doi:10.1007/s13105-023-00991-z

References
  1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520

  2. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2023;165(4):1080-1088. doi:10.1053/j.gastro.2023.06.013

  3. Di Mauro S, Scamporrino A, Filippello A, et al. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. Int J Mol Sci. 2021;22(21):11905. Published 2021 Nov 2. doi:10.3390/ijms222111905

  4. Hsu C, Caussy C, Imajo K, et al. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin Gastroenterol Hepatol. 2019;17(4):630-637.e8. doi:10.1016/j.cgh.2018.05.059

  5. Ilagan-Ying YC, Banini BA, Do A, Lam R, Lim JK. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Curr Gastroenterol Rep. 2023;25(10):213-224. doi:10.1007/s11894-023-00883-8

  6. Chen W, Gao Y, Xie W, et al. Genome-wide association analyses provide genetic and biochemical insights into natural variation in rice metabolism. Nat Genet. 2014;46(7):714-721. doi:10.1038/ng.3007

  7. Wu YL, Kumar R, Wang MF, et al. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol. 2021;27(34):5753-5763. doi:10.3748/wjg.v27.i34.5753

  8. Kaneva AM, Bojko ER. Fatty liver index (FLI): more than a marker of hepatic steatosis. J Physiol Biochem. Published online October 25, 2023. doi:10.1007/s13105-023-00991-z

Publications
Publications
Topics
Article Type
Display Headline
Role of Non-invasive Biomarkers in the Evaluation and Management of MASLD
Display Headline
Role of Non-invasive Biomarkers in the Evaluation and Management of MASLD
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
SLIDESHOW
Gate On Date
Fri, 05/24/2024 - 11:30
Un-Gate On Date
Fri, 05/24/2024 - 11:30
Use ProPublica
CFC Schedule Remove Status
Fri, 05/24/2024 - 11:30
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD),1 refers to a range of liver conditions characterized by the accumulation of fat in the liver due to metabolic factors. MASLD affects nearly 30% of the global population and is a prevalent cause of advanced liver disease.2 This disease can progress from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), which involves inflammation and liver cell damage—and unmitigated can lead to liver cirrhosis, liver failure, and liver cancer.

Clinicians' early identification and stratification of at-risk individuals may impact progression and regression, as only a minority of individuals with MASLD present with liver-related consequences.2 Although early identification and risk stratification may occur in gastroenterology and hepatology clinics, disease modifying interventions may occur outside of those settings. Continuously monitoring MASLD response to current treatments is also key. Histologic examination of the liver is the current established standard for assessing and monitoring this disease, grading necroinflammation, and staging hepatic fibrosis; however, the cost and invasiveness limit its routine and widespread use.2 Drug approvals independent of histology-based outcomes lay the groundwork for further standardization and validation of noninvasive tests (NITs) in the evaluation and management of MASLD. The latest AGA Clinical Practice Update (2023) can help healthcare professionals use NITs to identify patients who are at higher risk for MASLD progression for directed intervention.2 Ongoing research continues to refine the use of NITs in evaluating and managing MASLD; therefore, the landscape is likely to evolve and advance over time.

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media

Fluid Management in Acute Pancreatitis

Article Type
Changed
Wed, 06/05/2024 - 13:42
Display Headline
Fluid Management in Acute Pancreatitis
References
  1. Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis [published correction appears in Am J Gastroenterol. 2014;109(2):302]. Am J Gastroenterol. 2013;108(9):1400-1415. doi:10.1038/ajg.2013.218 

  1. de-Madaria E, Buxbaum JL, Maisonneuve P, et al. Aggressive or moderate fluid resuscitation in acute pancreatitis. N Engl J Med. 2022;387(11):989-1000. doi:10.1056/NEJMoa2202884 

  1. Zhao G, Zhang JG, Wu HS, et al. Effects of different resuscitation fluid on severe acute pancreatitis. World J Gastroenterol. 2013;19(13):2044-2052. doi:10.3748/wjg.v19.i13.2044 

  1. Guzmán-Calderón E, Diaz-Arocutipa C, Monge E. Lactate Ringer's versus normal saline in the management of acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Dig Dis Sci. 2022;67(8):4131-4139. doi:10.1007/s10620-021-07269-8 

  1. Hoste EA, Maitland K, Brudney CS, et al; ADQI XII Investigators Group. Four phases of intravenous fluid therapy: a conceptual model. Br J Anaesth. 2014;113(5):740-747. doi:10.1093/bja/aeu300 

  1. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 suppl 2):e1-e15. doi:10.1016/j.pan.2013.07.063 

  1. Machicado JD, Papachristou GI. Pharmacologic management and prevention of acute pancreatitis. Curr Opin Gastroenterol. 2019;35(5):460-467. doi:10.1097/MOG.0000000000000563 

Author and Disclosure Information

Jorge D. Machicado, MD, MPH

Clinical Assistant Professor
Division of Gastroenterology and Hepatology
University of Michigan
Ann Arbor, Michigan

Disclosures:
Serve(d) as a speaker for: Mauna Kea Technologies (Paris, France 10/21)
Received income in an amount equal to or greater than $250 from: Mauna Kea Technologies (Paris, France 10/21)

Publications
Topics
Author and Disclosure Information

Jorge D. Machicado, MD, MPH

Clinical Assistant Professor
Division of Gastroenterology and Hepatology
University of Michigan
Ann Arbor, Michigan

Disclosures:
Serve(d) as a speaker for: Mauna Kea Technologies (Paris, France 10/21)
Received income in an amount equal to or greater than $250 from: Mauna Kea Technologies (Paris, France 10/21)

Author and Disclosure Information

Jorge D. Machicado, MD, MPH

Clinical Assistant Professor
Division of Gastroenterology and Hepatology
University of Michigan
Ann Arbor, Michigan

Disclosures:
Serve(d) as a speaker for: Mauna Kea Technologies (Paris, France 10/21)
Received income in an amount equal to or greater than $250 from: Mauna Kea Technologies (Paris, France 10/21)

References
  1. Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis [published correction appears in Am J Gastroenterol. 2014;109(2):302]. Am J Gastroenterol. 2013;108(9):1400-1415. doi:10.1038/ajg.2013.218 

  1. de-Madaria E, Buxbaum JL, Maisonneuve P, et al. Aggressive or moderate fluid resuscitation in acute pancreatitis. N Engl J Med. 2022;387(11):989-1000. doi:10.1056/NEJMoa2202884 

  1. Zhao G, Zhang JG, Wu HS, et al. Effects of different resuscitation fluid on severe acute pancreatitis. World J Gastroenterol. 2013;19(13):2044-2052. doi:10.3748/wjg.v19.i13.2044 

  1. Guzmán-Calderón E, Diaz-Arocutipa C, Monge E. Lactate Ringer's versus normal saline in the management of acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Dig Dis Sci. 2022;67(8):4131-4139. doi:10.1007/s10620-021-07269-8 

  1. Hoste EA, Maitland K, Brudney CS, et al; ADQI XII Investigators Group. Four phases of intravenous fluid therapy: a conceptual model. Br J Anaesth. 2014;113(5):740-747. doi:10.1093/bja/aeu300 

  1. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 suppl 2):e1-e15. doi:10.1016/j.pan.2013.07.063 

  1. Machicado JD, Papachristou GI. Pharmacologic management and prevention of acute pancreatitis. Curr Opin Gastroenterol. 2019;35(5):460-467. doi:10.1097/MOG.0000000000000563 

References
  1. Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis [published correction appears in Am J Gastroenterol. 2014;109(2):302]. Am J Gastroenterol. 2013;108(9):1400-1415. doi:10.1038/ajg.2013.218 

  1. de-Madaria E, Buxbaum JL, Maisonneuve P, et al. Aggressive or moderate fluid resuscitation in acute pancreatitis. N Engl J Med. 2022;387(11):989-1000. doi:10.1056/NEJMoa2202884 

  1. Zhao G, Zhang JG, Wu HS, et al. Effects of different resuscitation fluid on severe acute pancreatitis. World J Gastroenterol. 2013;19(13):2044-2052. doi:10.3748/wjg.v19.i13.2044 

  1. Guzmán-Calderón E, Diaz-Arocutipa C, Monge E. Lactate Ringer's versus normal saline in the management of acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Dig Dis Sci. 2022;67(8):4131-4139. doi:10.1007/s10620-021-07269-8 

  1. Hoste EA, Maitland K, Brudney CS, et al; ADQI XII Investigators Group. Four phases of intravenous fluid therapy: a conceptual model. Br J Anaesth. 2014;113(5):740-747. doi:10.1093/bja/aeu300 

  1. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 suppl 2):e1-e15. doi:10.1016/j.pan.2013.07.063 

  1. Machicado JD, Papachristou GI. Pharmacologic management and prevention of acute pancreatitis. Curr Opin Gastroenterol. 2019;35(5):460-467. doi:10.1097/MOG.0000000000000563 

Publications
Publications
Topics
Article Type
Display Headline
Fluid Management in Acute Pancreatitis
Display Headline
Fluid Management in Acute Pancreatitis
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
SLIDESHOW
Gate On Date
Tue, 05/28/2024 - 11:00
Un-Gate On Date
Tue, 05/28/2024 - 11:00
Use ProPublica
CFC Schedule Remove Status
Tue, 05/28/2024 - 11:00
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Acute pancreatitis is marked by inflammation of the pancreas, potentially leading to organ failure and pancreatic necrosis. Early management relies heavily on intravenous (IV) fluid resuscitation. Initiating fluid resuscitation at an early stage can enhance pancreatic perfusion and maintain adequate systemic circulation, reducing the risk of pancreatic necrosis, hypovolemic shock, and organ failure.1

Recently, a series of randomized controlled trials have provided a clearer understanding of the type and rate of fluid administration that is the most beneficial for patients with acute pancreatitis.2-4 The approach to managing fluids in cases of acute pancreatitis may vary depending on the severity of the condition and individual patient factors. Fluids should be prescribed considering their composition (type of fluid), dosing (rate of administration), goals, potential risks, and contraindications.2,3 Close monitoring and assessment are essential components of effective fluid management of acute pancreatitis.2

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media

The Emerging Role of Liquid Biopsy in the Diagnosis and Management of CRC

Article Type
Changed
Wed, 06/05/2024 - 13:04
Display Headline
The Emerging Role of Liquid Biopsy in the Diagnosis and Management of CRC
References
  1. Key statistics for colorectal cancer. American Cancer Society. Revised January 13, 2023. Accessed November 30, 2023. https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html 

  1. Mazouji O, Ouhajjou A, Incitti R, Mansour H. Updates on clinical use of liquid biopsy in colorectal cancer screening, diagnosis, follow-up, and treatment guidance. Front Cell Dev Biol. 2021;9:660924. doi:10.3389/fcell.2021.660924 

  1. Vacante M, Ciuni R, Basile F, Biondi A. The liquid biopsy in the management of colorectal cancer: an overview. Biomedicines. 2020;8(9):308. doi:10.3390/biomedicines8090308 

  1. American Cancer Society. Colorectal cancer facts & figures 2020-2022. Published 2022. Accessed November 30, 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf 

  1. Johnson & Johnson. FDA clears Cellsearch™ circulating tumor cell test [news release]. Published February 27, 2008. Accessed November 30, 2023. https://johnsonandjohnson.gcs-web.com/news-releases/news-release-details/fda-clears-cellsearchtm-circulating-tumor-cell-test  

  1. US Food and Drug Administration. Summary of safety and effectiveness data, Epi proColon®. PMA number P130001. Published April 12, 2016. Accessed November 30, 2023. https://www.accessdata.fda.gov/cdrh_docs/pdf13/p130001b.pdf  

  1. FDA approves blood tests that can help guide cancer treatment. National Institutes of Health, National Cancer Institute. Published October 15, 2020. Accessed November 30, 2023. https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-guardant-360-foundation-one-cancer-liquid-biopsy  

  1. Foundation Medicine. US Food and Drug Administration (FDA) approves FoundationOne®LiquidCDx as a companion diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in combination with cetuximab to identify patients with BRAF V600E alterations in metastatic colorectal cancer [press release]. Published June 10, 2023. Accessed November 30, 2023. https://www.foundationmedicine.com/press-releases/f9b285eb-db6d-4f61-856c-3f1edb803937 
     

Author and Disclosure Information

David Lieberman, MD, AGAF
Professor
Department of Medicine
Division of Gastroenterology
Oregon Health and Science University
Staff Physician
Department of Medicine
Portland VA Medical Center
Portland, Oregon

Disclosures:
Serve(d) as a consultant for: UDX; Geneoscopy
Received income in an amount equal to or greater than $250 from: Geneoscopy

Publications
Topics
Author and Disclosure Information

David Lieberman, MD, AGAF
Professor
Department of Medicine
Division of Gastroenterology
Oregon Health and Science University
Staff Physician
Department of Medicine
Portland VA Medical Center
Portland, Oregon

Disclosures:
Serve(d) as a consultant for: UDX; Geneoscopy
Received income in an amount equal to or greater than $250 from: Geneoscopy

Author and Disclosure Information

David Lieberman, MD, AGAF
Professor
Department of Medicine
Division of Gastroenterology
Oregon Health and Science University
Staff Physician
Department of Medicine
Portland VA Medical Center
Portland, Oregon

Disclosures:
Serve(d) as a consultant for: UDX; Geneoscopy
Received income in an amount equal to or greater than $250 from: Geneoscopy

References
  1. Key statistics for colorectal cancer. American Cancer Society. Revised January 13, 2023. Accessed November 30, 2023. https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html 

  1. Mazouji O, Ouhajjou A, Incitti R, Mansour H. Updates on clinical use of liquid biopsy in colorectal cancer screening, diagnosis, follow-up, and treatment guidance. Front Cell Dev Biol. 2021;9:660924. doi:10.3389/fcell.2021.660924 

  1. Vacante M, Ciuni R, Basile F, Biondi A. The liquid biopsy in the management of colorectal cancer: an overview. Biomedicines. 2020;8(9):308. doi:10.3390/biomedicines8090308 

  1. American Cancer Society. Colorectal cancer facts & figures 2020-2022. Published 2022. Accessed November 30, 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf 

  1. Johnson & Johnson. FDA clears Cellsearch™ circulating tumor cell test [news release]. Published February 27, 2008. Accessed November 30, 2023. https://johnsonandjohnson.gcs-web.com/news-releases/news-release-details/fda-clears-cellsearchtm-circulating-tumor-cell-test  

  1. US Food and Drug Administration. Summary of safety and effectiveness data, Epi proColon®. PMA number P130001. Published April 12, 2016. Accessed November 30, 2023. https://www.accessdata.fda.gov/cdrh_docs/pdf13/p130001b.pdf  

  1. FDA approves blood tests that can help guide cancer treatment. National Institutes of Health, National Cancer Institute. Published October 15, 2020. Accessed November 30, 2023. https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-guardant-360-foundation-one-cancer-liquid-biopsy  

  1. Foundation Medicine. US Food and Drug Administration (FDA) approves FoundationOne®LiquidCDx as a companion diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in combination with cetuximab to identify patients with BRAF V600E alterations in metastatic colorectal cancer [press release]. Published June 10, 2023. Accessed November 30, 2023. https://www.foundationmedicine.com/press-releases/f9b285eb-db6d-4f61-856c-3f1edb803937 
     

References
  1. Key statistics for colorectal cancer. American Cancer Society. Revised January 13, 2023. Accessed November 30, 2023. https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html 

  1. Mazouji O, Ouhajjou A, Incitti R, Mansour H. Updates on clinical use of liquid biopsy in colorectal cancer screening, diagnosis, follow-up, and treatment guidance. Front Cell Dev Biol. 2021;9:660924. doi:10.3389/fcell.2021.660924 

  1. Vacante M, Ciuni R, Basile F, Biondi A. The liquid biopsy in the management of colorectal cancer: an overview. Biomedicines. 2020;8(9):308. doi:10.3390/biomedicines8090308 

  1. American Cancer Society. Colorectal cancer facts & figures 2020-2022. Published 2022. Accessed November 30, 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf 

  1. Johnson & Johnson. FDA clears Cellsearch™ circulating tumor cell test [news release]. Published February 27, 2008. Accessed November 30, 2023. https://johnsonandjohnson.gcs-web.com/news-releases/news-release-details/fda-clears-cellsearchtm-circulating-tumor-cell-test  

  1. US Food and Drug Administration. Summary of safety and effectiveness data, Epi proColon®. PMA number P130001. Published April 12, 2016. Accessed November 30, 2023. https://www.accessdata.fda.gov/cdrh_docs/pdf13/p130001b.pdf  

  1. FDA approves blood tests that can help guide cancer treatment. National Institutes of Health, National Cancer Institute. Published October 15, 2020. Accessed November 30, 2023. https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-guardant-360-foundation-one-cancer-liquid-biopsy  

  1. Foundation Medicine. US Food and Drug Administration (FDA) approves FoundationOne®LiquidCDx as a companion diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in combination with cetuximab to identify patients with BRAF V600E alterations in metastatic colorectal cancer [press release]. Published June 10, 2023. Accessed November 30, 2023. https://www.foundationmedicine.com/press-releases/f9b285eb-db6d-4f61-856c-3f1edb803937 
     

Publications
Publications
Topics
Article Type
Display Headline
The Emerging Role of Liquid Biopsy in the Diagnosis and Management of CRC
Display Headline
The Emerging Role of Liquid Biopsy in the Diagnosis and Management of CRC
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
SLIDESHOW
Gate On Date
Tue, 05/28/2024 - 10:30
Un-Gate On Date
Tue, 05/28/2024 - 10:30
Use ProPublica
CFC Schedule Remove Status
Tue, 05/28/2024 - 10:30
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Colorectal cancer (CRC) is the third most common cancer in the United States, and early detection and monitoring are crucial for improving patient outcomes.1 Liquid biopsy (LB) is a revolutionary approach that may offer a non-invasive way to diagnose and manage CRC. The history of LB for CRC reflects a progression from early attempts to detect biomarkers in blood to the current era of precise genetic analysis using circulating tumor deoxyribonucleic acid (ctDNA) and analyzed with next-generation sequencing. The technology has significantly improved over time, leading to the potential for integration into clinical practice and to provide more personalized and effective CRC management.2

LB offers several potential advantages for CRC screening compared to traditional non-invasive screening with a stool sample, or invasive screening with colonoscopy. A blood test that could identify high-risk individuals who need colonoscopy is exciting, because it is possible that adherence to screening would be improved with LB. However, there are many challenges. Reduction of CRC mortality or incidence will depend on the ability of the test to accurately detect individuals with early-stage cancer or precancerous advanced polyps. It is not clear if the biology of such lesions would result in an adequate signal in blood if the lesion were not invasive. Test performance also depends on completion of colonoscopy if individuals have an abnormal LB. Testing methods, cost consideration, and clinical validation of performance will need to be addressed.3 As the technology advances, the role of LB in CRC screening will likely evolve and expand.

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media

Eosinophilic Gastrointestinal Diseases: Beyond EoE

Article Type
Changed
Wed, 06/05/2024 - 12:33
Display Headline
Eosinophilic Gastrointestinal Diseases: Beyond EoE
References
  1. Dellon ES, Gonsalves N, Abonia JP, et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022;20(11):2474-2484.e3. doi:10.1016/j.cgh.2022.02.017
  2. Naramore S, Gupta SK. Nonesophageal eosinophilic gastrointestinal disorders: clinical care and future directions. J Pediatr Gastroenterol Nutr. 2018;67(3):318-321. doi:10.1097/MPG.0000000000002040
  3. Kinoshita Y, Sanuki T. Review of non-eosinophilic esophagitis-eosinophilic gastrointestinal disease (non-EoE-EGID) and a case series of twenty-eight affected patients. Biomolecules. 2023;13(9):1417. doi:10.3390/biom13091417
  4. Gonsalves N, Doerfler B, Zalewski A, et al. Prospective study of an amino acid-based elemental diet in an eosinophilic gastritis and gastroenteritis nutrition trial. J Allergy Clin Immunol. 2023;152(3):676-688. doi:10.1016/j.jaci.2023.05.024
  5. Oshima T. Biologic therapies targeting eosinophilic gastrointestinal diseases. Intern Med. 2023;62(23):3429-3430. doi:10.2169/internalmedicine.1911-23
  6. Pineton de Chambrun G, Gonzalez F, Canva JY, et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011;9(11):950-956.e1. doi:10.1016/j.cgh.2011.07.017
  7. Hirano I, Collins MH, King E, et al; CEGIR Investigators. Prospective endoscopic activity assessment for eosinophilic gastritis in a multi-site cohort. Am J Gastroenterol. 2022;117(3):413-423. doi:10.14309/ajg.0000000000001625
  8. Pesek RD, Reed CC, Muir AB, et al; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium. Am J Gastroenterol. 2019;114(6):984-994. doi:10.14309/ajg.0000000000000228
Author and Disclosure Information

Nirmala Gonsalves, MD, AGAF, FACG
Professor of Medicine
Division of Gastroenterology & Hepatology
Northwestern University
Feinberg School of Medicine
Co-Director of Eosinophilic Gastrointestinal Disorders Program
Northwestern Memorial Hospital
Chicago, Illinois

Disclosures:
Serve(d) as a consultant for: AstraZeneca; Allakos; AbbVie; BMS; Sanofi-Regeneron
Serve(d) as a speaker or a member of a speakers bureau for: Sanofi-Regeneron

Publications
Topics
Author and Disclosure Information

Nirmala Gonsalves, MD, AGAF, FACG
Professor of Medicine
Division of Gastroenterology & Hepatology
Northwestern University
Feinberg School of Medicine
Co-Director of Eosinophilic Gastrointestinal Disorders Program
Northwestern Memorial Hospital
Chicago, Illinois

Disclosures:
Serve(d) as a consultant for: AstraZeneca; Allakos; AbbVie; BMS; Sanofi-Regeneron
Serve(d) as a speaker or a member of a speakers bureau for: Sanofi-Regeneron

Author and Disclosure Information

Nirmala Gonsalves, MD, AGAF, FACG
Professor of Medicine
Division of Gastroenterology & Hepatology
Northwestern University
Feinberg School of Medicine
Co-Director of Eosinophilic Gastrointestinal Disorders Program
Northwestern Memorial Hospital
Chicago, Illinois

Disclosures:
Serve(d) as a consultant for: AstraZeneca; Allakos; AbbVie; BMS; Sanofi-Regeneron
Serve(d) as a speaker or a member of a speakers bureau for: Sanofi-Regeneron

References
  1. Dellon ES, Gonsalves N, Abonia JP, et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022;20(11):2474-2484.e3. doi:10.1016/j.cgh.2022.02.017
  2. Naramore S, Gupta SK. Nonesophageal eosinophilic gastrointestinal disorders: clinical care and future directions. J Pediatr Gastroenterol Nutr. 2018;67(3):318-321. doi:10.1097/MPG.0000000000002040
  3. Kinoshita Y, Sanuki T. Review of non-eosinophilic esophagitis-eosinophilic gastrointestinal disease (non-EoE-EGID) and a case series of twenty-eight affected patients. Biomolecules. 2023;13(9):1417. doi:10.3390/biom13091417
  4. Gonsalves N, Doerfler B, Zalewski A, et al. Prospective study of an amino acid-based elemental diet in an eosinophilic gastritis and gastroenteritis nutrition trial. J Allergy Clin Immunol. 2023;152(3):676-688. doi:10.1016/j.jaci.2023.05.024
  5. Oshima T. Biologic therapies targeting eosinophilic gastrointestinal diseases. Intern Med. 2023;62(23):3429-3430. doi:10.2169/internalmedicine.1911-23
  6. Pineton de Chambrun G, Gonzalez F, Canva JY, et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011;9(11):950-956.e1. doi:10.1016/j.cgh.2011.07.017
  7. Hirano I, Collins MH, King E, et al; CEGIR Investigators. Prospective endoscopic activity assessment for eosinophilic gastritis in a multi-site cohort. Am J Gastroenterol. 2022;117(3):413-423. doi:10.14309/ajg.0000000000001625
  8. Pesek RD, Reed CC, Muir AB, et al; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium. Am J Gastroenterol. 2019;114(6):984-994. doi:10.14309/ajg.0000000000000228
References
  1. Dellon ES, Gonsalves N, Abonia JP, et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022;20(11):2474-2484.e3. doi:10.1016/j.cgh.2022.02.017
  2. Naramore S, Gupta SK. Nonesophageal eosinophilic gastrointestinal disorders: clinical care and future directions. J Pediatr Gastroenterol Nutr. 2018;67(3):318-321. doi:10.1097/MPG.0000000000002040
  3. Kinoshita Y, Sanuki T. Review of non-eosinophilic esophagitis-eosinophilic gastrointestinal disease (non-EoE-EGID) and a case series of twenty-eight affected patients. Biomolecules. 2023;13(9):1417. doi:10.3390/biom13091417
  4. Gonsalves N, Doerfler B, Zalewski A, et al. Prospective study of an amino acid-based elemental diet in an eosinophilic gastritis and gastroenteritis nutrition trial. J Allergy Clin Immunol. 2023;152(3):676-688. doi:10.1016/j.jaci.2023.05.024
  5. Oshima T. Biologic therapies targeting eosinophilic gastrointestinal diseases. Intern Med. 2023;62(23):3429-3430. doi:10.2169/internalmedicine.1911-23
  6. Pineton de Chambrun G, Gonzalez F, Canva JY, et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011;9(11):950-956.e1. doi:10.1016/j.cgh.2011.07.017
  7. Hirano I, Collins MH, King E, et al; CEGIR Investigators. Prospective endoscopic activity assessment for eosinophilic gastritis in a multi-site cohort. Am J Gastroenterol. 2022;117(3):413-423. doi:10.14309/ajg.0000000000001625
  8. Pesek RD, Reed CC, Muir AB, et al; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium. Am J Gastroenterol. 2019;114(6):984-994. doi:10.14309/ajg.0000000000000228
Publications
Publications
Topics
Article Type
Display Headline
Eosinophilic Gastrointestinal Diseases: Beyond EoE
Display Headline
Eosinophilic Gastrointestinal Diseases: Beyond EoE
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Thu, 05/30/2024 - 09:45
Un-Gate On Date
Thu, 05/30/2024 - 09:45
Use ProPublica
CFC Schedule Remove Status
Thu, 05/30/2024 - 09:45
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

While great strides have been made in the last few decades to improve our understanding of the diagnosis and treatment of eosinophilic esophagitis (EoE), there is much to be learned about treating other non-EoE eosinophilic gastrointestinal diseases (EGIDs). One of the first challenges in diagnosing these rare conditions was developing a  consistent nomenclature. For instance, the term eosinophilic gastroenteritis was used previously as a blanket term for any type of eosinophilic gastrointestinal infiltration, but its varying uses and lack of consistency led to confusion with the diagnosis. To help improve clinical and research advances in disorders of eosinophils below the diaphragm, in 2022 an international committee convened to create a consensus on standardizing EGID nomenclature. This important milestone created an EGID nomenclature system to specify the location of inflammation in a more precise and defined way.1 Additional challenges with diagnosing and managing the non-EoE EGIDs include the heterogenous symptom presentation, which can lead to delay in diagnosis. Furthermore, the lack of an FDA-approved treatment for non-EoE EGIDs creates additional hurdles for treatment.

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media

Subungual Nodule in a Pediatric Patient

Article Type
Changed
Wed, 06/05/2024 - 16:09
Display Headline
Subungual Nodule in a Pediatric Patient

The Diagnosis: Subungual Exostosis

Subungual exostosis should be considered as a possible cause of an exophytic subungual nodule in a young active female. In our patient, the involvement of the great toe was a clue, as the hallux is the most common location of subungual exostosis. The patient’s age and sex also were supportive, as subungual exostosis is most common in female children and adolescents— particularly those who are active, as trauma is thought to play a possible role in development of this benign tumor.1-3 Radiography is the preferred modality for diagnosis; in our case, it showed a trabecular bony overgrowth (Figure 1), which confirmed the diagnosis. Subungual exostosis is a rare, benign, osteocartilaginous tumor of trabecular bone. The etiology is unknown but is hypothesized to be related to trauma, infection, or activation of a cartilaginous cyst.1,3 The subungual nodule may be asymptomatic or painful. Disruption and elevation of the nail plate is common.4 The differential diagnosis includes amelanotic melanoma, fibroma, fibrokeratoma, osteochondroma, pyogenic granuloma, squamous cell carcinoma, glomus tumor, and verruca vulgaris, among others.5

FIGURE 1. Radiography demonstrated exostosis extending from the distal medial cortical surface of the left first distal phalanx, confirming the diagnosis of subungual exostosis.

Physical examination demonstrates a firm, fixed, subungual nodule, often with an accompanying nail deformity. Further workup is required to confirm the benign nature of the lesion and exclude nail tumors such as melanoma or squamous cell carcinoma. Radiography is the gold standard for diagnosis, demonstrating a trabecular bony overgrowth.6 Performing a radiograph as the initial diagnostic test spares the patient from unnecessary procedures such as biopsy or expensive imaging techniques such as magnetic resonance imaging. Early lesions may not demonstrate sufficient bone formation shown on radiography. In these situations, a combination of dermoscopy and histopathologic examination may aid in diagnosis (Figure 2).4 Vascular ectasia, hyperkeratosis, onycholysis, and ulceration are the most common findings on dermoscopy (in ascending order).7 Histopathology typically demonstrates a base or stalk of normal-appearing trabecular bone with a fibrocartilage cap.8 However, initial clinical workup via radiography allows for the least-invasive and highest-yield intervention. Clinical suspicion for this condition is important, as it can be diagnosed with noninvasive inexpensive imaging rather than biopsy or more specialized imaging modalities. Appropriate recognition can save young patients from unnecessary and expensive procedures. Treatment typically involves surgical excision; to prevent regrowth, removal of the lesion at the base of the bone is recommended.2

FIGURE 2. Dermoscopy of a flesh-colored, sessile, subungual nodule that was diagnosed as subungual exostosis.

Although amelanotic melanoma also can manifest as a subungual nail tumor, it would be unusual in a young child and would not be expected to show characteristic changes on radiography. A glomus tumor would be painful, is more common on the fingers than on the toes, and typically has a bluish hue.9 Verruca vulgaris can occur subungually but is more common around the nailfold and often has the characteristic dermoscopic finding of thrombosed capillaries. It also would not be expected to show characteristic radiographic findings. Osteochondroma can occur in young patients and can appear clinically similar to subungual exostosis; however, it typically is painful.10

References
  1. Pascoal D, Balaco I, Alves C, et al. Subungual exostosis—treatment results with preservation of the nail bed. J Pediatr Orthop B. 2020;29:382-386.
  2. Yousefian F, Davis B, Browning JC. Pediatric subungual exostosis. Cutis. 2021;108:256-257.
  3. Chiheb S, Slimani Y, Karam R, et al. Subungual exostosis: a case series of 48 patients. Skin Appendage Disord. 2021;7:475-479.
  4. Zhang W, Gu L, Fan H, et al. Subungual exostosis with an unusual dermoscopic feature. JAAD Case Rep. 2020;6:725-726.
  5. Demirdag HG, Tugrul Ayanoglu B, Akay BN. Dermoscopic features of subungual exostosis. Australas J Dermatol. 2019;60:E138-E141.
  6. Tritto M, Mirkin G, Hao X. Subungual exostosis on the right hallux. J Am Podiatr Med Assoc. 2021;111.
  7. Piccolo V, Argenziano G, Alessandrini AM, et al. Dermoscopy of subungual exostosis: a retrospective study of 10 patients. Dermatology. 2017;233:80-85.
  8. Lee SK, Jung MS, Lee YH, et al. Two distinctive subungual pathologies: subungual exostosis and subungual osteochondroma. Foot Ankle Int. 2007;28:595-601. doi:10.3113/FAI.2007.0595
  9. Samaniego E, Crespo A, Sanz A. Key diagnostic features and treatment of subungual glomus tumor. Actas Dermosifiliogr. 2009;100:875-882.
  10. Glick S. Subungual osteochondroma of the third toe. Consult.360. 2013;12.
Article PDF
Author and Disclosure Information

From the Mayo Clinic, Rochester, Minnesota. Rewan M. Abdelwahab is from the Alix School of Medicine, and Drs. Kim and Link are from the Department of Dermatology.

The authors report no conflict of interest.

Correspondence: Jenny L. Link, MD, Department of Dermatology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905 ([email protected]).

Issue
Cutis - 113(6)
Publications
Topics
Page Number
249-250
Sections
Author and Disclosure Information

From the Mayo Clinic, Rochester, Minnesota. Rewan M. Abdelwahab is from the Alix School of Medicine, and Drs. Kim and Link are from the Department of Dermatology.

The authors report no conflict of interest.

Correspondence: Jenny L. Link, MD, Department of Dermatology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905 ([email protected]).

Author and Disclosure Information

From the Mayo Clinic, Rochester, Minnesota. Rewan M. Abdelwahab is from the Alix School of Medicine, and Drs. Kim and Link are from the Department of Dermatology.

The authors report no conflict of interest.

Correspondence: Jenny L. Link, MD, Department of Dermatology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905 ([email protected]).

Article PDF
Article PDF

The Diagnosis: Subungual Exostosis

Subungual exostosis should be considered as a possible cause of an exophytic subungual nodule in a young active female. In our patient, the involvement of the great toe was a clue, as the hallux is the most common location of subungual exostosis. The patient’s age and sex also were supportive, as subungual exostosis is most common in female children and adolescents— particularly those who are active, as trauma is thought to play a possible role in development of this benign tumor.1-3 Radiography is the preferred modality for diagnosis; in our case, it showed a trabecular bony overgrowth (Figure 1), which confirmed the diagnosis. Subungual exostosis is a rare, benign, osteocartilaginous tumor of trabecular bone. The etiology is unknown but is hypothesized to be related to trauma, infection, or activation of a cartilaginous cyst.1,3 The subungual nodule may be asymptomatic or painful. Disruption and elevation of the nail plate is common.4 The differential diagnosis includes amelanotic melanoma, fibroma, fibrokeratoma, osteochondroma, pyogenic granuloma, squamous cell carcinoma, glomus tumor, and verruca vulgaris, among others.5

FIGURE 1. Radiography demonstrated exostosis extending from the distal medial cortical surface of the left first distal phalanx, confirming the diagnosis of subungual exostosis.

Physical examination demonstrates a firm, fixed, subungual nodule, often with an accompanying nail deformity. Further workup is required to confirm the benign nature of the lesion and exclude nail tumors such as melanoma or squamous cell carcinoma. Radiography is the gold standard for diagnosis, demonstrating a trabecular bony overgrowth.6 Performing a radiograph as the initial diagnostic test spares the patient from unnecessary procedures such as biopsy or expensive imaging techniques such as magnetic resonance imaging. Early lesions may not demonstrate sufficient bone formation shown on radiography. In these situations, a combination of dermoscopy and histopathologic examination may aid in diagnosis (Figure 2).4 Vascular ectasia, hyperkeratosis, onycholysis, and ulceration are the most common findings on dermoscopy (in ascending order).7 Histopathology typically demonstrates a base or stalk of normal-appearing trabecular bone with a fibrocartilage cap.8 However, initial clinical workup via radiography allows for the least-invasive and highest-yield intervention. Clinical suspicion for this condition is important, as it can be diagnosed with noninvasive inexpensive imaging rather than biopsy or more specialized imaging modalities. Appropriate recognition can save young patients from unnecessary and expensive procedures. Treatment typically involves surgical excision; to prevent regrowth, removal of the lesion at the base of the bone is recommended.2

FIGURE 2. Dermoscopy of a flesh-colored, sessile, subungual nodule that was diagnosed as subungual exostosis.

Although amelanotic melanoma also can manifest as a subungual nail tumor, it would be unusual in a young child and would not be expected to show characteristic changes on radiography. A glomus tumor would be painful, is more common on the fingers than on the toes, and typically has a bluish hue.9 Verruca vulgaris can occur subungually but is more common around the nailfold and often has the characteristic dermoscopic finding of thrombosed capillaries. It also would not be expected to show characteristic radiographic findings. Osteochondroma can occur in young patients and can appear clinically similar to subungual exostosis; however, it typically is painful.10

The Diagnosis: Subungual Exostosis

Subungual exostosis should be considered as a possible cause of an exophytic subungual nodule in a young active female. In our patient, the involvement of the great toe was a clue, as the hallux is the most common location of subungual exostosis. The patient’s age and sex also were supportive, as subungual exostosis is most common in female children and adolescents— particularly those who are active, as trauma is thought to play a possible role in development of this benign tumor.1-3 Radiography is the preferred modality for diagnosis; in our case, it showed a trabecular bony overgrowth (Figure 1), which confirmed the diagnosis. Subungual exostosis is a rare, benign, osteocartilaginous tumor of trabecular bone. The etiology is unknown but is hypothesized to be related to trauma, infection, or activation of a cartilaginous cyst.1,3 The subungual nodule may be asymptomatic or painful. Disruption and elevation of the nail plate is common.4 The differential diagnosis includes amelanotic melanoma, fibroma, fibrokeratoma, osteochondroma, pyogenic granuloma, squamous cell carcinoma, glomus tumor, and verruca vulgaris, among others.5

FIGURE 1. Radiography demonstrated exostosis extending from the distal medial cortical surface of the left first distal phalanx, confirming the diagnosis of subungual exostosis.

Physical examination demonstrates a firm, fixed, subungual nodule, often with an accompanying nail deformity. Further workup is required to confirm the benign nature of the lesion and exclude nail tumors such as melanoma or squamous cell carcinoma. Radiography is the gold standard for diagnosis, demonstrating a trabecular bony overgrowth.6 Performing a radiograph as the initial diagnostic test spares the patient from unnecessary procedures such as biopsy or expensive imaging techniques such as magnetic resonance imaging. Early lesions may not demonstrate sufficient bone formation shown on radiography. In these situations, a combination of dermoscopy and histopathologic examination may aid in diagnosis (Figure 2).4 Vascular ectasia, hyperkeratosis, onycholysis, and ulceration are the most common findings on dermoscopy (in ascending order).7 Histopathology typically demonstrates a base or stalk of normal-appearing trabecular bone with a fibrocartilage cap.8 However, initial clinical workup via radiography allows for the least-invasive and highest-yield intervention. Clinical suspicion for this condition is important, as it can be diagnosed with noninvasive inexpensive imaging rather than biopsy or more specialized imaging modalities. Appropriate recognition can save young patients from unnecessary and expensive procedures. Treatment typically involves surgical excision; to prevent regrowth, removal of the lesion at the base of the bone is recommended.2

FIGURE 2. Dermoscopy of a flesh-colored, sessile, subungual nodule that was diagnosed as subungual exostosis.

Although amelanotic melanoma also can manifest as a subungual nail tumor, it would be unusual in a young child and would not be expected to show characteristic changes on radiography. A glomus tumor would be painful, is more common on the fingers than on the toes, and typically has a bluish hue.9 Verruca vulgaris can occur subungually but is more common around the nailfold and often has the characteristic dermoscopic finding of thrombosed capillaries. It also would not be expected to show characteristic radiographic findings. Osteochondroma can occur in young patients and can appear clinically similar to subungual exostosis; however, it typically is painful.10

References
  1. Pascoal D, Balaco I, Alves C, et al. Subungual exostosis—treatment results with preservation of the nail bed. J Pediatr Orthop B. 2020;29:382-386.
  2. Yousefian F, Davis B, Browning JC. Pediatric subungual exostosis. Cutis. 2021;108:256-257.
  3. Chiheb S, Slimani Y, Karam R, et al. Subungual exostosis: a case series of 48 patients. Skin Appendage Disord. 2021;7:475-479.
  4. Zhang W, Gu L, Fan H, et al. Subungual exostosis with an unusual dermoscopic feature. JAAD Case Rep. 2020;6:725-726.
  5. Demirdag HG, Tugrul Ayanoglu B, Akay BN. Dermoscopic features of subungual exostosis. Australas J Dermatol. 2019;60:E138-E141.
  6. Tritto M, Mirkin G, Hao X. Subungual exostosis on the right hallux. J Am Podiatr Med Assoc. 2021;111.
  7. Piccolo V, Argenziano G, Alessandrini AM, et al. Dermoscopy of subungual exostosis: a retrospective study of 10 patients. Dermatology. 2017;233:80-85.
  8. Lee SK, Jung MS, Lee YH, et al. Two distinctive subungual pathologies: subungual exostosis and subungual osteochondroma. Foot Ankle Int. 2007;28:595-601. doi:10.3113/FAI.2007.0595
  9. Samaniego E, Crespo A, Sanz A. Key diagnostic features and treatment of subungual glomus tumor. Actas Dermosifiliogr. 2009;100:875-882.
  10. Glick S. Subungual osteochondroma of the third toe. Consult.360. 2013;12.
References
  1. Pascoal D, Balaco I, Alves C, et al. Subungual exostosis—treatment results with preservation of the nail bed. J Pediatr Orthop B. 2020;29:382-386.
  2. Yousefian F, Davis B, Browning JC. Pediatric subungual exostosis. Cutis. 2021;108:256-257.
  3. Chiheb S, Slimani Y, Karam R, et al. Subungual exostosis: a case series of 48 patients. Skin Appendage Disord. 2021;7:475-479.
  4. Zhang W, Gu L, Fan H, et al. Subungual exostosis with an unusual dermoscopic feature. JAAD Case Rep. 2020;6:725-726.
  5. Demirdag HG, Tugrul Ayanoglu B, Akay BN. Dermoscopic features of subungual exostosis. Australas J Dermatol. 2019;60:E138-E141.
  6. Tritto M, Mirkin G, Hao X. Subungual exostosis on the right hallux. J Am Podiatr Med Assoc. 2021;111.
  7. Piccolo V, Argenziano G, Alessandrini AM, et al. Dermoscopy of subungual exostosis: a retrospective study of 10 patients. Dermatology. 2017;233:80-85.
  8. Lee SK, Jung MS, Lee YH, et al. Two distinctive subungual pathologies: subungual exostosis and subungual osteochondroma. Foot Ankle Int. 2007;28:595-601. doi:10.3113/FAI.2007.0595
  9. Samaniego E, Crespo A, Sanz A. Key diagnostic features and treatment of subungual glomus tumor. Actas Dermosifiliogr. 2009;100:875-882.
  10. Glick S. Subungual osteochondroma of the third toe. Consult.360. 2013;12.
Issue
Cutis - 113(6)
Issue
Cutis - 113(6)
Page Number
249-250
Page Number
249-250
Publications
Publications
Topics
Article Type
Display Headline
Subungual Nodule in a Pediatric Patient
Display Headline
Subungual Nodule in a Pediatric Patient
Sections
Questionnaire Body

A 13-year-old girl presented to her pediatrician with a small pink bump under the left great toenail of 8 months’ duration that was slowly growing. Months later, she developed an ingrown nail on the same toe, which was treated with partial nail avulsion by the pediatrician. Given continued nail dystrophy and a visible bump under the nail, the patient was referred to dermatology. Physical examination revealed a subungual, flesh-colored, sessile nodule causing distortion of the nail plate on the left great toe with associated intermittent redness and swelling. She denied wearing new shoes or experiencing any pain, pruritus, or purulent drainage or bleeding from the lesion. She reported being physically active and playing tennis.

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 06/05/2024 - 09:15
Un-Gate On Date
Wed, 06/05/2024 - 09:15
Use ProPublica
CFC Schedule Remove Status
Wed, 06/05/2024 - 09:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Aquatic Antagonists: Seaweed Dermatitis (Lyngbya majuscula)

Article Type
Changed
Fri, 06/07/2024 - 11:04
Display Headline

Aquatic Antagonists: Seaweed Dermatitis (Lyngbya majuscula)

The filamentous cyanobacterium Lyngbya majuscula causes irritant contact dermatitis in beachgoers, fishers, and divers in tropical and subtropical marine environments worldwide.1 If fragments of L majuscula lodge in swimmers’ bathing suits, the toxins can become trapped against the skin and cause seaweed dermatitis.2 With climate change resulting in warmer oceans and more extreme storms, L majuscula blooms likely will become more frequent and widespread, thereby increasing the risk for human exposure.3,4 Herein, we describe the irritants that lead to dermatitis, clinical presentation, and prevention and management of seaweed dermatitis.

Identifying Features and Distribution of Plant

Lyngbya majuscula belongs to the family Oscillatoriaceae; these cyanobacteria grow as filaments and exhibit slow oscillating movements. Commonly referred to as blanketweed or mermaid’s hair due to its appearance, L majuscula grows fine hairlike clumps resembling a mass of olive-colored matted hair.1 Its thin filaments are 10- to 30-cm long and vary in color from red to white to brown.5 Microscopically, a rouleauxlike arrangement of discs provides the structure of each filament.6

First identified in Hawaii in 1912, L majuscula was not associated with seaweed dermatitis or dermatotoxicity by the medical community until the first outbreak occurred in Oahu in 1958, though fishermen and beachgoers previously had recognized a relationship between this particular seaweed and skin irritation.5,7 The first reporting included 125 confirmed cases, with many more mild unreported cases suspected.6 Now reported in about 100 locations worldwide, seaweed dermatitis outbreaks have occurred in Australia; Okinawa, Japan; Florida; and the Hawaiian and Marshall islands.1,2

Exposure to Seaweed

Lyngbya majuscula produces more than 70 biologically active compounds that irritate the skin, eyes, and respiratory system.2,8 It grows in marine and estuarine environments attached to seagrass, sand, and bedrock at depths of up to 30 m. Warm waters and maximal sunlight provide optimal growth conditions for L majuscula; therefore, the greatest risk for exposure occurs in the Northern and Southern hemispheres in the 1- to 2-month period following their summer solstices.5 Runoff during heavy rainfall, which is rich in soil extracts such as phosphorous, iron, and organic carbon, stimulates L majuscula growth and contributes to increased algal blooms.4

Dermatitis and Irritants

The dermatoxins Lyngbyatoxin A (LA) and debromoaplysiatoxin (DAT) cause the inflammatory and necrotic appearance of seaweed dermatitis.1,2,5,8 Lyngbyatoxin A is an indole alkaloid that is closely related to telocidin B, a poisonous compound associated with Streptomyces bacteria.9 Sampling of L majuscula and extraction of the dermatoxin, along with human and animal studies, confirmed DAT irritates the skin and induces dermatitis.5,6Stylocheilus longicauda (sea hare) feeds on L majuscula and contains isolates of DAT in its digestive tract.

Samples of L majuscula taken from several Hawaiian Islands where seaweed dermatitis outbreaks have occurred were examined for differences in toxicities via 6-hour patch tests on human skin.6 The samples obtained from the windward side of Oahu contained DAT and aplysiatoxin, while those obtained from the leeward side and Kahala Beach primarily contained LA. Although DAT and LA are vastly different in their molecular structures, testing elicited the same biologic response and induced the same level of skin irritation.6 Interestingly, not all strands of L majuscula produced LA and DAT and caused seaweed dermatitis; those that did lead to irritation were more red in color than nontoxic blooms.5,9

Cutaneous Manifestations

Seaweed dermatitis resembles chemical and thermal burns, ranging from a mild skin rash to severe contact dermatitis with itchy, swollen, ulcerated lesions.1,7 Patients typically develop a burning or itching sensation beneath their bathing suit or wetsuit that progresses to an erythematous papulovesicular eruption 2 to 24 hours after exposure.2,6 Within a week, vesicles and bullae desquamate, leaving behind tender erosions.1,2,6,8 Inframammary lesions are common in females and scrotal swelling in males.1,6 There is no known association between length of time spent in the water and severity of symptoms.5

Most reactions to L majuscula occur from exposure in the water; however, particles that become aerosolized during strong winds or storms can cause seaweed dermatitis on the face. Inhalation of L majuscula may lead to mucous membrane ulceration and pulmonary edema.1,5,6 Noncutaneous manifestations of seaweed dermatitis include headache, fatigue, and swelling of the eyes, nose, and throat (Figures 1 and 2).1,5

Prevention and Management

To prevent seaweed dermatitis, avoid swimming in ocean water during L majuscula blooms,10 which frequently occur following the summer solstices in the Northern and Southern hemispheres.5 The National Centers for Coastal Ocean Science Harmful Algae Bloom Monitoring System provides real-time access to algae bloom locations.11 Although this monitoring system is not specific to L majuscula, it may be helpful in determining where potential blooms are. Wearing protective clothing such as coveralls may benefit individuals who enter the water during blooms, but it does not guarantee protection.10

FIGURE 1. A punch biopsy of an abdominal lesion in a patient with seaweed dermatitis (Lyngbya majuscula) showed an intraepidermal blister with superficial desquamation at the top (H&E, original
magnification ×40). Photograph courtesy of Scott Norton, MD, MPH, MSc (Washington, DC).

FIGURE 2. Classic erythematous papulovesicular rash on the abdomen of a patient with seaweed dermatitis (Lyngbya majuscula). Photograph courtesy of Scott Norton, MD, MPH, MSc (Washington, DC).

Currently, there is no treatment for seaweed dermatitis, but symptom management may reduce discomfort and pain. Washing affected skin with soap and water within an hour of exposure may help reduce the severity of seaweed dermatitis, though studies have shown mixed results.6,7 Application of cool compresses and soothing ointments (eg, calamine) provide symptomatic relief and promote healing.7 The dermatitis typically self-resolves within 1 week.

References
  1. Werner K, Marquart L, Norton S. Lyngbya dermatitis (toxic seaweed dermatitis). Int J Dermatol. 2011;51:59-62. doi:10.1111/j.1365-4632.2011.05042.x
  2. Osborne N, Shaw G. Dermatitis associated with exposure to a marine cyanobacterium during recreational water exposure. BMC Dermatol. 2008;8:5. doi:10.1186/1471-5945-8-5
  3. Hays G, Richardson A, Robinson C. Climate change and marine plankton. Trends Ecol Evol. 2005;20:337-344. doi:10.1016/j.tree.2005.03.004
  4. Albert S, O’Neil J, Udy J, et al. Blooms of the cyanobacterium Lyngbya majuscula in costal Queensland, Australia: disparate sites, common factors. Mar Pollut Bull. 2004;51:428-437. doi:10.1016/j.marpolbul.2004.10.016
  5. Osborne N, Webb P, Shaw G. The toxins of Lyngbya majuscula and their human and ecological health effects. Environ Int. 2001;27:381-392. doi:10.1016/s0160-4120(01)00098-8
  6. Izumi A, Moore R. Seaweed ( Lyngbya majuscula ) dermatitis . Clin Dermatol . 1987;5:92-100. doi:10.1016/s0738-081x(87)80014-7
  7. Grauer F, Arnold H. Seaweed dermatitis: first report of a dermatitis-producing marine alga. Arch Dermatol. 1961; 84:720-732. doi:10.1001/archderm.1961.01580170014003
  8. Taylor M, Stahl-Timmins W, Redshaw C, et al. Toxic alkaloids in Lyngbya majuscula and related tropical marine cyanobacteria. Harmful Algae . 2014;31:1-8. doi:10.1016/j.hal.2013.09.003
  9. Cardellina J, Marner F, Moore R. Seaweed dermatitis: structure of lyngbyatoxin A. Science. 1979;204:193-195. doi:10.1126/science.107586
  10. Osborne N. Occupational dermatitis caused by Lyngbya majuscule in Australia. Int J Dermatol . 2012;5:122-123. doi:10.1111/j.1365-4632.2009.04455.x
  11. Harmful Algal Bloom Monitoring System. National Centers for Coastal Ocean Science. Accessed May 23, 2024. https://coastalscience.noaa.gov/research/stressor-impacts-mitigation/hab-monitoring-system/
Article PDF
Author and Disclosure Information

 

Dr. Hill is from the University of South Carolina School of Medicine, Greenville. Dr. Fulton is from Spartanburg Regional Medical Center, South Carolina. Dr. McGovern is from Fort Wayne Dermatology Consultants, Indiana.

The authors report no conflict of interest.

The images are in the public domain.

Correspondence: Kathleen L. Hill, MD, 607 Grove Rd, Greenville, SC 29605 ([email protected]).

Cutis. 2024 May;113(5):E38-E40. doi:10.12788/cutis.1032

Issue
Cutis - 113(5)
Publications
Topics
Page Number
E38-E40
Sections
Author and Disclosure Information

 

Dr. Hill is from the University of South Carolina School of Medicine, Greenville. Dr. Fulton is from Spartanburg Regional Medical Center, South Carolina. Dr. McGovern is from Fort Wayne Dermatology Consultants, Indiana.

The authors report no conflict of interest.

The images are in the public domain.

Correspondence: Kathleen L. Hill, MD, 607 Grove Rd, Greenville, SC 29605 ([email protected]).

Cutis. 2024 May;113(5):E38-E40. doi:10.12788/cutis.1032

Author and Disclosure Information

 

Dr. Hill is from the University of South Carolina School of Medicine, Greenville. Dr. Fulton is from Spartanburg Regional Medical Center, South Carolina. Dr. McGovern is from Fort Wayne Dermatology Consultants, Indiana.

The authors report no conflict of interest.

The images are in the public domain.

Correspondence: Kathleen L. Hill, MD, 607 Grove Rd, Greenville, SC 29605 ([email protected]).

Cutis. 2024 May;113(5):E38-E40. doi:10.12788/cutis.1032

Article PDF
Article PDF

The filamentous cyanobacterium Lyngbya majuscula causes irritant contact dermatitis in beachgoers, fishers, and divers in tropical and subtropical marine environments worldwide.1 If fragments of L majuscula lodge in swimmers’ bathing suits, the toxins can become trapped against the skin and cause seaweed dermatitis.2 With climate change resulting in warmer oceans and more extreme storms, L majuscula blooms likely will become more frequent and widespread, thereby increasing the risk for human exposure.3,4 Herein, we describe the irritants that lead to dermatitis, clinical presentation, and prevention and management of seaweed dermatitis.

Identifying Features and Distribution of Plant

Lyngbya majuscula belongs to the family Oscillatoriaceae; these cyanobacteria grow as filaments and exhibit slow oscillating movements. Commonly referred to as blanketweed or mermaid’s hair due to its appearance, L majuscula grows fine hairlike clumps resembling a mass of olive-colored matted hair.1 Its thin filaments are 10- to 30-cm long and vary in color from red to white to brown.5 Microscopically, a rouleauxlike arrangement of discs provides the structure of each filament.6

First identified in Hawaii in 1912, L majuscula was not associated with seaweed dermatitis or dermatotoxicity by the medical community until the first outbreak occurred in Oahu in 1958, though fishermen and beachgoers previously had recognized a relationship between this particular seaweed and skin irritation.5,7 The first reporting included 125 confirmed cases, with many more mild unreported cases suspected.6 Now reported in about 100 locations worldwide, seaweed dermatitis outbreaks have occurred in Australia; Okinawa, Japan; Florida; and the Hawaiian and Marshall islands.1,2

Exposure to Seaweed

Lyngbya majuscula produces more than 70 biologically active compounds that irritate the skin, eyes, and respiratory system.2,8 It grows in marine and estuarine environments attached to seagrass, sand, and bedrock at depths of up to 30 m. Warm waters and maximal sunlight provide optimal growth conditions for L majuscula; therefore, the greatest risk for exposure occurs in the Northern and Southern hemispheres in the 1- to 2-month period following their summer solstices.5 Runoff during heavy rainfall, which is rich in soil extracts such as phosphorous, iron, and organic carbon, stimulates L majuscula growth and contributes to increased algal blooms.4

Dermatitis and Irritants

The dermatoxins Lyngbyatoxin A (LA) and debromoaplysiatoxin (DAT) cause the inflammatory and necrotic appearance of seaweed dermatitis.1,2,5,8 Lyngbyatoxin A is an indole alkaloid that is closely related to telocidin B, a poisonous compound associated with Streptomyces bacteria.9 Sampling of L majuscula and extraction of the dermatoxin, along with human and animal studies, confirmed DAT irritates the skin and induces dermatitis.5,6Stylocheilus longicauda (sea hare) feeds on L majuscula and contains isolates of DAT in its digestive tract.

Samples of L majuscula taken from several Hawaiian Islands where seaweed dermatitis outbreaks have occurred were examined for differences in toxicities via 6-hour patch tests on human skin.6 The samples obtained from the windward side of Oahu contained DAT and aplysiatoxin, while those obtained from the leeward side and Kahala Beach primarily contained LA. Although DAT and LA are vastly different in their molecular structures, testing elicited the same biologic response and induced the same level of skin irritation.6 Interestingly, not all strands of L majuscula produced LA and DAT and caused seaweed dermatitis; those that did lead to irritation were more red in color than nontoxic blooms.5,9

Cutaneous Manifestations

Seaweed dermatitis resembles chemical and thermal burns, ranging from a mild skin rash to severe contact dermatitis with itchy, swollen, ulcerated lesions.1,7 Patients typically develop a burning or itching sensation beneath their bathing suit or wetsuit that progresses to an erythematous papulovesicular eruption 2 to 24 hours after exposure.2,6 Within a week, vesicles and bullae desquamate, leaving behind tender erosions.1,2,6,8 Inframammary lesions are common in females and scrotal swelling in males.1,6 There is no known association between length of time spent in the water and severity of symptoms.5

Most reactions to L majuscula occur from exposure in the water; however, particles that become aerosolized during strong winds or storms can cause seaweed dermatitis on the face. Inhalation of L majuscula may lead to mucous membrane ulceration and pulmonary edema.1,5,6 Noncutaneous manifestations of seaweed dermatitis include headache, fatigue, and swelling of the eyes, nose, and throat (Figures 1 and 2).1,5

Prevention and Management

To prevent seaweed dermatitis, avoid swimming in ocean water during L majuscula blooms,10 which frequently occur following the summer solstices in the Northern and Southern hemispheres.5 The National Centers for Coastal Ocean Science Harmful Algae Bloom Monitoring System provides real-time access to algae bloom locations.11 Although this monitoring system is not specific to L majuscula, it may be helpful in determining where potential blooms are. Wearing protective clothing such as coveralls may benefit individuals who enter the water during blooms, but it does not guarantee protection.10

FIGURE 1. A punch biopsy of an abdominal lesion in a patient with seaweed dermatitis (Lyngbya majuscula) showed an intraepidermal blister with superficial desquamation at the top (H&E, original
magnification ×40). Photograph courtesy of Scott Norton, MD, MPH, MSc (Washington, DC).

FIGURE 2. Classic erythematous papulovesicular rash on the abdomen of a patient with seaweed dermatitis (Lyngbya majuscula). Photograph courtesy of Scott Norton, MD, MPH, MSc (Washington, DC).

Currently, there is no treatment for seaweed dermatitis, but symptom management may reduce discomfort and pain. Washing affected skin with soap and water within an hour of exposure may help reduce the severity of seaweed dermatitis, though studies have shown mixed results.6,7 Application of cool compresses and soothing ointments (eg, calamine) provide symptomatic relief and promote healing.7 The dermatitis typically self-resolves within 1 week.

The filamentous cyanobacterium Lyngbya majuscula causes irritant contact dermatitis in beachgoers, fishers, and divers in tropical and subtropical marine environments worldwide.1 If fragments of L majuscula lodge in swimmers’ bathing suits, the toxins can become trapped against the skin and cause seaweed dermatitis.2 With climate change resulting in warmer oceans and more extreme storms, L majuscula blooms likely will become more frequent and widespread, thereby increasing the risk for human exposure.3,4 Herein, we describe the irritants that lead to dermatitis, clinical presentation, and prevention and management of seaweed dermatitis.

Identifying Features and Distribution of Plant

Lyngbya majuscula belongs to the family Oscillatoriaceae; these cyanobacteria grow as filaments and exhibit slow oscillating movements. Commonly referred to as blanketweed or mermaid’s hair due to its appearance, L majuscula grows fine hairlike clumps resembling a mass of olive-colored matted hair.1 Its thin filaments are 10- to 30-cm long and vary in color from red to white to brown.5 Microscopically, a rouleauxlike arrangement of discs provides the structure of each filament.6

First identified in Hawaii in 1912, L majuscula was not associated with seaweed dermatitis or dermatotoxicity by the medical community until the first outbreak occurred in Oahu in 1958, though fishermen and beachgoers previously had recognized a relationship between this particular seaweed and skin irritation.5,7 The first reporting included 125 confirmed cases, with many more mild unreported cases suspected.6 Now reported in about 100 locations worldwide, seaweed dermatitis outbreaks have occurred in Australia; Okinawa, Japan; Florida; and the Hawaiian and Marshall islands.1,2

Exposure to Seaweed

Lyngbya majuscula produces more than 70 biologically active compounds that irritate the skin, eyes, and respiratory system.2,8 It grows in marine and estuarine environments attached to seagrass, sand, and bedrock at depths of up to 30 m. Warm waters and maximal sunlight provide optimal growth conditions for L majuscula; therefore, the greatest risk for exposure occurs in the Northern and Southern hemispheres in the 1- to 2-month period following their summer solstices.5 Runoff during heavy rainfall, which is rich in soil extracts such as phosphorous, iron, and organic carbon, stimulates L majuscula growth and contributes to increased algal blooms.4

Dermatitis and Irritants

The dermatoxins Lyngbyatoxin A (LA) and debromoaplysiatoxin (DAT) cause the inflammatory and necrotic appearance of seaweed dermatitis.1,2,5,8 Lyngbyatoxin A is an indole alkaloid that is closely related to telocidin B, a poisonous compound associated with Streptomyces bacteria.9 Sampling of L majuscula and extraction of the dermatoxin, along with human and animal studies, confirmed DAT irritates the skin and induces dermatitis.5,6Stylocheilus longicauda (sea hare) feeds on L majuscula and contains isolates of DAT in its digestive tract.

Samples of L majuscula taken from several Hawaiian Islands where seaweed dermatitis outbreaks have occurred were examined for differences in toxicities via 6-hour patch tests on human skin.6 The samples obtained from the windward side of Oahu contained DAT and aplysiatoxin, while those obtained from the leeward side and Kahala Beach primarily contained LA. Although DAT and LA are vastly different in their molecular structures, testing elicited the same biologic response and induced the same level of skin irritation.6 Interestingly, not all strands of L majuscula produced LA and DAT and caused seaweed dermatitis; those that did lead to irritation were more red in color than nontoxic blooms.5,9

Cutaneous Manifestations

Seaweed dermatitis resembles chemical and thermal burns, ranging from a mild skin rash to severe contact dermatitis with itchy, swollen, ulcerated lesions.1,7 Patients typically develop a burning or itching sensation beneath their bathing suit or wetsuit that progresses to an erythematous papulovesicular eruption 2 to 24 hours after exposure.2,6 Within a week, vesicles and bullae desquamate, leaving behind tender erosions.1,2,6,8 Inframammary lesions are common in females and scrotal swelling in males.1,6 There is no known association between length of time spent in the water and severity of symptoms.5

Most reactions to L majuscula occur from exposure in the water; however, particles that become aerosolized during strong winds or storms can cause seaweed dermatitis on the face. Inhalation of L majuscula may lead to mucous membrane ulceration and pulmonary edema.1,5,6 Noncutaneous manifestations of seaweed dermatitis include headache, fatigue, and swelling of the eyes, nose, and throat (Figures 1 and 2).1,5

Prevention and Management

To prevent seaweed dermatitis, avoid swimming in ocean water during L majuscula blooms,10 which frequently occur following the summer solstices in the Northern and Southern hemispheres.5 The National Centers for Coastal Ocean Science Harmful Algae Bloom Monitoring System provides real-time access to algae bloom locations.11 Although this monitoring system is not specific to L majuscula, it may be helpful in determining where potential blooms are. Wearing protective clothing such as coveralls may benefit individuals who enter the water during blooms, but it does not guarantee protection.10

FIGURE 1. A punch biopsy of an abdominal lesion in a patient with seaweed dermatitis (Lyngbya majuscula) showed an intraepidermal blister with superficial desquamation at the top (H&E, original
magnification ×40). Photograph courtesy of Scott Norton, MD, MPH, MSc (Washington, DC).

FIGURE 2. Classic erythematous papulovesicular rash on the abdomen of a patient with seaweed dermatitis (Lyngbya majuscula). Photograph courtesy of Scott Norton, MD, MPH, MSc (Washington, DC).

Currently, there is no treatment for seaweed dermatitis, but symptom management may reduce discomfort and pain. Washing affected skin with soap and water within an hour of exposure may help reduce the severity of seaweed dermatitis, though studies have shown mixed results.6,7 Application of cool compresses and soothing ointments (eg, calamine) provide symptomatic relief and promote healing.7 The dermatitis typically self-resolves within 1 week.

References
  1. Werner K, Marquart L, Norton S. Lyngbya dermatitis (toxic seaweed dermatitis). Int J Dermatol. 2011;51:59-62. doi:10.1111/j.1365-4632.2011.05042.x
  2. Osborne N, Shaw G. Dermatitis associated with exposure to a marine cyanobacterium during recreational water exposure. BMC Dermatol. 2008;8:5. doi:10.1186/1471-5945-8-5
  3. Hays G, Richardson A, Robinson C. Climate change and marine plankton. Trends Ecol Evol. 2005;20:337-344. doi:10.1016/j.tree.2005.03.004
  4. Albert S, O’Neil J, Udy J, et al. Blooms of the cyanobacterium Lyngbya majuscula in costal Queensland, Australia: disparate sites, common factors. Mar Pollut Bull. 2004;51:428-437. doi:10.1016/j.marpolbul.2004.10.016
  5. Osborne N, Webb P, Shaw G. The toxins of Lyngbya majuscula and their human and ecological health effects. Environ Int. 2001;27:381-392. doi:10.1016/s0160-4120(01)00098-8
  6. Izumi A, Moore R. Seaweed ( Lyngbya majuscula ) dermatitis . Clin Dermatol . 1987;5:92-100. doi:10.1016/s0738-081x(87)80014-7
  7. Grauer F, Arnold H. Seaweed dermatitis: first report of a dermatitis-producing marine alga. Arch Dermatol. 1961; 84:720-732. doi:10.1001/archderm.1961.01580170014003
  8. Taylor M, Stahl-Timmins W, Redshaw C, et al. Toxic alkaloids in Lyngbya majuscula and related tropical marine cyanobacteria. Harmful Algae . 2014;31:1-8. doi:10.1016/j.hal.2013.09.003
  9. Cardellina J, Marner F, Moore R. Seaweed dermatitis: structure of lyngbyatoxin A. Science. 1979;204:193-195. doi:10.1126/science.107586
  10. Osborne N. Occupational dermatitis caused by Lyngbya majuscule in Australia. Int J Dermatol . 2012;5:122-123. doi:10.1111/j.1365-4632.2009.04455.x
  11. Harmful Algal Bloom Monitoring System. National Centers for Coastal Ocean Science. Accessed May 23, 2024. https://coastalscience.noaa.gov/research/stressor-impacts-mitigation/hab-monitoring-system/
References
  1. Werner K, Marquart L, Norton S. Lyngbya dermatitis (toxic seaweed dermatitis). Int J Dermatol. 2011;51:59-62. doi:10.1111/j.1365-4632.2011.05042.x
  2. Osborne N, Shaw G. Dermatitis associated with exposure to a marine cyanobacterium during recreational water exposure. BMC Dermatol. 2008;8:5. doi:10.1186/1471-5945-8-5
  3. Hays G, Richardson A, Robinson C. Climate change and marine plankton. Trends Ecol Evol. 2005;20:337-344. doi:10.1016/j.tree.2005.03.004
  4. Albert S, O’Neil J, Udy J, et al. Blooms of the cyanobacterium Lyngbya majuscula in costal Queensland, Australia: disparate sites, common factors. Mar Pollut Bull. 2004;51:428-437. doi:10.1016/j.marpolbul.2004.10.016
  5. Osborne N, Webb P, Shaw G. The toxins of Lyngbya majuscula and their human and ecological health effects. Environ Int. 2001;27:381-392. doi:10.1016/s0160-4120(01)00098-8
  6. Izumi A, Moore R. Seaweed ( Lyngbya majuscula ) dermatitis . Clin Dermatol . 1987;5:92-100. doi:10.1016/s0738-081x(87)80014-7
  7. Grauer F, Arnold H. Seaweed dermatitis: first report of a dermatitis-producing marine alga. Arch Dermatol. 1961; 84:720-732. doi:10.1001/archderm.1961.01580170014003
  8. Taylor M, Stahl-Timmins W, Redshaw C, et al. Toxic alkaloids in Lyngbya majuscula and related tropical marine cyanobacteria. Harmful Algae . 2014;31:1-8. doi:10.1016/j.hal.2013.09.003
  9. Cardellina J, Marner F, Moore R. Seaweed dermatitis: structure of lyngbyatoxin A. Science. 1979;204:193-195. doi:10.1126/science.107586
  10. Osborne N. Occupational dermatitis caused by Lyngbya majuscule in Australia. Int J Dermatol . 2012;5:122-123. doi:10.1111/j.1365-4632.2009.04455.x
  11. Harmful Algal Bloom Monitoring System. National Centers for Coastal Ocean Science. Accessed May 23, 2024. https://coastalscience.noaa.gov/research/stressor-impacts-mitigation/hab-monitoring-system/
Issue
Cutis - 113(5)
Issue
Cutis - 113(5)
Page Number
E38-E40
Page Number
E38-E40
Publications
Publications
Topics
Article Type
Display Headline

Aquatic Antagonists: Seaweed Dermatitis (Lyngbya majuscula)

Display Headline

Aquatic Antagonists: Seaweed Dermatitis (Lyngbya majuscula)

Sections
Inside the Article

 

PRACTICE POINTS

  • Lyngbya majuscula causes seaweed dermatitis in swimmers and can be prevented by avoiding rough turbid waters in areas known to have L majuscula blooms.
  • Seaweed dermatitis should be included in the differential diagnosis for erythematous papulovesicular rashes manifesting in patients who recently have spent time in the ocean.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Plantar Hyperpigmentation

Article Type
Changed
Wed, 06/12/2024 - 14:36

Plantar hyperpigmentation (also known as plantar melanosis [increased melanin], volar pigmented macules, benign racial melanosis, acral pigmentation, acral ethnic melanosis, or mottled hyperpigmentation of the plantar surface) is a benign finding in many individuals and is especially prevalent in those with darker skin tones. Acral refers to manifestation on the hands and feet, volar on the palms and soles, and plantar on the soles only. Here, we focus on plantar hyper-pigmentation. We use the terms ethnic and racial interchangeably.

It is critically important to differentiate benign hyperpigmentation, which is common in patients with skin of color, from melanoma. Although rare, Black patients in the United States experience high morbidity and mortality from acral melanoma, which often is diagnosed late in the disease course.1

There are many causes of hyperpigmentation on the plantar surfaces, including benign ethnic melanosis, nevi, melanoma, infections such as syphilis and tinea nigra, conditions such as Peutz-Jeghers syndrome and Laugier-Hunziker syndrome, and postinflammatory hyperpigmentation secondary to atopic dermatitis and psoriasis. We focus on the most common causes, ethnic melanosis and nevi, as well as melanoma, which is the deadliest cause.

 

Epidemiology

In a 1980 study (N=251), Black Americans had a high incidence of plantar hyperpigmentation, with 52% of affected patients having dark brown skin and 31% having light brown skin.2

The epidemiology of melanoma varies by race/ethnicity. Melanoma in Black individuals is relatively rare, with an annual incidence of approximately 1 in 100,000 individuals.3 However, when individuals with skin of color develop melanoma, they are more likely than their White counterparts to have acral melanoma (acral lentiginous melanoma), one of the deadliest types.1 In a case series of Black patients with melanoma (N=48) from 2 tertiary care centers in Texas, 30 of 40 primary cutaneous melanomas (75%) were located on acral skin.4 Overall, 13 patients developed stage IV disease and 12 died due to disease progression. All patients who developed distant metastases or died of melanoma had acral melanoma.4 Individuals of Asian descent also have a high incidence of acral melanoma, as shown in research from Japan.5-9

Key Clinical Features in Individuals With Darker Skin Tones

Dermoscopy is an evidence-based clinical examination method for earlier diagnosis of cutaneous melanoma, including on acral skin.10,11 Benign nevi on the volar skin as well as the palms and soles tend to have one of these 3 dermoscopic patterns: parallel furrow, lattice, or irregular fibrillar. The pattern that is most predictive of volar melanoma is the parallel ridge pattern (PRP) (Figures A and B [insets]), which showed a high specificity (99.0%) and very high negative predictive value (97.7%) for malignant melanoma in a Japanese population.7 The PRP data from this study cannot be applied reliably to Black individuals, especially because benign ethnic melanosis and other benign conditions can demonstrate PRP.12 Reliance on the PRP as a diagnostic clue could result in unneccessary biopsies in as many as 50% of Black patients with benign plantar hyperpigmentation.2 Furthermore, biopsies of the plantar surface can be painful and cause pain while walking.

It has been suggested that PRP seen on dermoscopy in benign hyperpigmentation such as ethnic melanosis and nevi may preserve the acrosyringia (eccrine gland openings on the ridge), whereas PRP in melanoma may obliterate the acrosyringia.13 This observation is based on case reports only and needs further study. However, if validated, it could be a useful diagnostic clue.

 

 

Worth noting

In a retrospective cohort study of skin cancer in Black individuals (n=165) at a New York City–based cancer center from 2000 to 2020, 68% of patients were diagnosed with melanomas—80% were the acral subtype and 75% displayed a PRP. However, the surrounding uninvolved background skin, which was visible in most cases, also demonstrated a PRP.14 Because of the high morbidity and mortality rates of acral melanoma, clinicians should biopsy or immediately refer patients with concerning plantar hyperpigmentation to a dermatologist.

 

Health disparity highlight

The mortality rate for acral melanoma in Black patients is disproportionately high for the following reasons15,16:

• Patients and health care providers do not expect to see melanoma in Black patients (it truly is rare!), so screening and education on sun protection are limited.

• Benign ethnic melanosis makes it more difficult to distinguish between early acral melanoma and benign skin changes.

• Black patients and other US patient populations with skin of color may be less likely to have health insurance, which contributes to inequities in access to health care. As of 2022, the uninsured rates for nonelderly American Indian and Alaska Native, Hispanic, Native Hawaiian and Other Pacific Islander, Black, and White individuals were 19.1%, 18.0%, 12.7%, 10.0%, and 6.6%, respectively.17

Multi-institutional registries could improve understanding of acral melanoma in Black patients.4 More studies are needed to help differentiate between the dermoscopic finding of PRP in benign ethnic melanosis vs malignant melanoma.

References

1. Huang K, Fan J, Misra S. Acral lentiginous melanoma: incidence and survival in the United States, 2006-2015: an analysis of the SEER registry. J Surg Res. 2020;251:329-339. doi:10.1016/j.jss.2020.02.010

2. Coleman WP, Gately LE, Krementz AB, et al. Nevi, lentigines, and melanomas in blacks. Arch Dermatol. 1980;116:548-551.

3. Centers for Disease Control and Prevention. Melanoma Incidence and Mortality, United States: 2012-2016. USCS Data Brief, no. 9. Centers for Disease Control and Prevention, US Department of Health and Human Services; 2019. https://www.cdc.gov/cancer/uscs/about/data-briefs/no9-melanoma-incidence-mortality-UnitedStates-2012-2016.htm

4. Wix SN, Brown AB, Heberton M, et al. Clinical features and outcomes of black patients with melanoma. JAMA Dermatol. 2024;160:328-333. doi:10.1001/jamadermatol.2023.5789

5. Saida T, Koga H. Dermoscopic patterns of acral melanocytic nevi: their variations, changes, and significance. Arch Dermatol. 2007;143:1423-1426. doi:10.1001/archderm.143.11.1423

6. Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol. 2011;38:25-34. doi:10.1111/j.1346-8138.2010.01174.x

7. Saida T, Miyazaki A, Oguchi S. Significance of dermoscopic patterns in detecting malignant melanoma on acral volar skin: results of a multicenter study in Japan. Arch Dermatol. 2004;140:1233-1238. doi:10.1001/archderm.140.10.1233

8. Saida T, Koga H, Uhara H. Dermoscopy for acral melanocytic lesions: revision of the 3-step algorithm and refined definition of the regular and irregular fibrillar pattern. Dermatol Pract Concept. 2022;12:e2022123. doi:10.5826/dpc.1203a123

9. Heath CR, Usatine RP. Melanoma. Cutis. 2022;109:284-285. doi:10.12788/cutis.0513.

10. Dinnes J, Deeks JJ, Chuchu N, et al; Cochrane Skin Cancer Diagnostic Test Accuracy Group. Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults. Cochrane Database Syst Rev. 2018; 12:CD011901. doi:10.1002/14651858.CD011901.pub2

11. Vestergaard ME, Macaskill P, Holt PE, et al. Dermoscopy compared with naked-eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol. 2008;159:669-676. doi:10.1111/j.1365-2133.2008.08713.x

12. Phan A, Dalle S, Marcilly MC, et al. Benign dermoscopic parallel ridge pattern variants. Arch Dermatol. 2011;147:634. doi:10.1001/archdermatol.2011.47

13. Fracaroli TS, Lavorato FG, Maceira JP, et al. Parallel ridge pattern on dermoscopy: observation in non-melanoma cases. An Bras Dermatol. 2013;88:646-648. doi:10.1590/abd1806-4841.20132058

14. Manci RN, Dauscher M, Marchetti MA, et al. Features of skin cancer in black individuals: a single-institution retrospective cohort study. Dermatol Pract Concept. 2022;12:e2022075. doi:10.5826/dpc.1202a75

15. Dawes SM, Tsai S, Gittleman H, et al. Racial disparities in melanoma survival. J Am Acad Dematol. 2016;75:983-991. doi:10.1016/j.jaad.2016.06.006

16. Ingrassia JP, Stein JA, Levine A, et al. Diagnosis and management of acral pigmented lesions. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2023;49:926-931. doi:10.1097/DSS.0000000000003891

17. Hill L, Artiga S, Damico A. Health coverage by race and ethnicity, 2010-2022. Kaiser Family Foundation. Published January 11, 2024. Accessed May 9, 2024. https://www.kff.org/racial-equity-and-health-policy/issue-brief/health-coverage-by-race-and-ethnicity

Article PDF
Author and Disclosure Information

Richard P. Usatine, MDa; Candrice R. Heath, MDb

aFamily and Community Medicine and Dermatology, and Cutaneous Surgery, University of Texas Health, San Antonio

bDepartment of Urban Health and Population, Science, Center for Urban Bioethics, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania

Issue
Federal Practitioner - 41(6)
Publications
Topics
Page Number
170-171
Sections
Author and Disclosure Information

Richard P. Usatine, MDa; Candrice R. Heath, MDb

aFamily and Community Medicine and Dermatology, and Cutaneous Surgery, University of Texas Health, San Antonio

bDepartment of Urban Health and Population, Science, Center for Urban Bioethics, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania

Author and Disclosure Information

Richard P. Usatine, MDa; Candrice R. Heath, MDb

aFamily and Community Medicine and Dermatology, and Cutaneous Surgery, University of Texas Health, San Antonio

bDepartment of Urban Health and Population, Science, Center for Urban Bioethics, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania

Article PDF
Article PDF

Plantar hyperpigmentation (also known as plantar melanosis [increased melanin], volar pigmented macules, benign racial melanosis, acral pigmentation, acral ethnic melanosis, or mottled hyperpigmentation of the plantar surface) is a benign finding in many individuals and is especially prevalent in those with darker skin tones. Acral refers to manifestation on the hands and feet, volar on the palms and soles, and plantar on the soles only. Here, we focus on plantar hyper-pigmentation. We use the terms ethnic and racial interchangeably.

It is critically important to differentiate benign hyperpigmentation, which is common in patients with skin of color, from melanoma. Although rare, Black patients in the United States experience high morbidity and mortality from acral melanoma, which often is diagnosed late in the disease course.1

There are many causes of hyperpigmentation on the plantar surfaces, including benign ethnic melanosis, nevi, melanoma, infections such as syphilis and tinea nigra, conditions such as Peutz-Jeghers syndrome and Laugier-Hunziker syndrome, and postinflammatory hyperpigmentation secondary to atopic dermatitis and psoriasis. We focus on the most common causes, ethnic melanosis and nevi, as well as melanoma, which is the deadliest cause.

 

Epidemiology

In a 1980 study (N=251), Black Americans had a high incidence of plantar hyperpigmentation, with 52% of affected patients having dark brown skin and 31% having light brown skin.2

The epidemiology of melanoma varies by race/ethnicity. Melanoma in Black individuals is relatively rare, with an annual incidence of approximately 1 in 100,000 individuals.3 However, when individuals with skin of color develop melanoma, they are more likely than their White counterparts to have acral melanoma (acral lentiginous melanoma), one of the deadliest types.1 In a case series of Black patients with melanoma (N=48) from 2 tertiary care centers in Texas, 30 of 40 primary cutaneous melanomas (75%) were located on acral skin.4 Overall, 13 patients developed stage IV disease and 12 died due to disease progression. All patients who developed distant metastases or died of melanoma had acral melanoma.4 Individuals of Asian descent also have a high incidence of acral melanoma, as shown in research from Japan.5-9

Key Clinical Features in Individuals With Darker Skin Tones

Dermoscopy is an evidence-based clinical examination method for earlier diagnosis of cutaneous melanoma, including on acral skin.10,11 Benign nevi on the volar skin as well as the palms and soles tend to have one of these 3 dermoscopic patterns: parallel furrow, lattice, or irregular fibrillar. The pattern that is most predictive of volar melanoma is the parallel ridge pattern (PRP) (Figures A and B [insets]), which showed a high specificity (99.0%) and very high negative predictive value (97.7%) for malignant melanoma in a Japanese population.7 The PRP data from this study cannot be applied reliably to Black individuals, especially because benign ethnic melanosis and other benign conditions can demonstrate PRP.12 Reliance on the PRP as a diagnostic clue could result in unneccessary biopsies in as many as 50% of Black patients with benign plantar hyperpigmentation.2 Furthermore, biopsies of the plantar surface can be painful and cause pain while walking.

It has been suggested that PRP seen on dermoscopy in benign hyperpigmentation such as ethnic melanosis and nevi may preserve the acrosyringia (eccrine gland openings on the ridge), whereas PRP in melanoma may obliterate the acrosyringia.13 This observation is based on case reports only and needs further study. However, if validated, it could be a useful diagnostic clue.

 

 

Worth noting

In a retrospective cohort study of skin cancer in Black individuals (n=165) at a New York City–based cancer center from 2000 to 2020, 68% of patients were diagnosed with melanomas—80% were the acral subtype and 75% displayed a PRP. However, the surrounding uninvolved background skin, which was visible in most cases, also demonstrated a PRP.14 Because of the high morbidity and mortality rates of acral melanoma, clinicians should biopsy or immediately refer patients with concerning plantar hyperpigmentation to a dermatologist.

 

Health disparity highlight

The mortality rate for acral melanoma in Black patients is disproportionately high for the following reasons15,16:

• Patients and health care providers do not expect to see melanoma in Black patients (it truly is rare!), so screening and education on sun protection are limited.

• Benign ethnic melanosis makes it more difficult to distinguish between early acral melanoma and benign skin changes.

• Black patients and other US patient populations with skin of color may be less likely to have health insurance, which contributes to inequities in access to health care. As of 2022, the uninsured rates for nonelderly American Indian and Alaska Native, Hispanic, Native Hawaiian and Other Pacific Islander, Black, and White individuals were 19.1%, 18.0%, 12.7%, 10.0%, and 6.6%, respectively.17

Multi-institutional registries could improve understanding of acral melanoma in Black patients.4 More studies are needed to help differentiate between the dermoscopic finding of PRP in benign ethnic melanosis vs malignant melanoma.

Plantar hyperpigmentation (also known as plantar melanosis [increased melanin], volar pigmented macules, benign racial melanosis, acral pigmentation, acral ethnic melanosis, or mottled hyperpigmentation of the plantar surface) is a benign finding in many individuals and is especially prevalent in those with darker skin tones. Acral refers to manifestation on the hands and feet, volar on the palms and soles, and plantar on the soles only. Here, we focus on plantar hyper-pigmentation. We use the terms ethnic and racial interchangeably.

It is critically important to differentiate benign hyperpigmentation, which is common in patients with skin of color, from melanoma. Although rare, Black patients in the United States experience high morbidity and mortality from acral melanoma, which often is diagnosed late in the disease course.1

There are many causes of hyperpigmentation on the plantar surfaces, including benign ethnic melanosis, nevi, melanoma, infections such as syphilis and tinea nigra, conditions such as Peutz-Jeghers syndrome and Laugier-Hunziker syndrome, and postinflammatory hyperpigmentation secondary to atopic dermatitis and psoriasis. We focus on the most common causes, ethnic melanosis and nevi, as well as melanoma, which is the deadliest cause.

 

Epidemiology

In a 1980 study (N=251), Black Americans had a high incidence of plantar hyperpigmentation, with 52% of affected patients having dark brown skin and 31% having light brown skin.2

The epidemiology of melanoma varies by race/ethnicity. Melanoma in Black individuals is relatively rare, with an annual incidence of approximately 1 in 100,000 individuals.3 However, when individuals with skin of color develop melanoma, they are more likely than their White counterparts to have acral melanoma (acral lentiginous melanoma), one of the deadliest types.1 In a case series of Black patients with melanoma (N=48) from 2 tertiary care centers in Texas, 30 of 40 primary cutaneous melanomas (75%) were located on acral skin.4 Overall, 13 patients developed stage IV disease and 12 died due to disease progression. All patients who developed distant metastases or died of melanoma had acral melanoma.4 Individuals of Asian descent also have a high incidence of acral melanoma, as shown in research from Japan.5-9

Key Clinical Features in Individuals With Darker Skin Tones

Dermoscopy is an evidence-based clinical examination method for earlier diagnosis of cutaneous melanoma, including on acral skin.10,11 Benign nevi on the volar skin as well as the palms and soles tend to have one of these 3 dermoscopic patterns: parallel furrow, lattice, or irregular fibrillar. The pattern that is most predictive of volar melanoma is the parallel ridge pattern (PRP) (Figures A and B [insets]), which showed a high specificity (99.0%) and very high negative predictive value (97.7%) for malignant melanoma in a Japanese population.7 The PRP data from this study cannot be applied reliably to Black individuals, especially because benign ethnic melanosis and other benign conditions can demonstrate PRP.12 Reliance on the PRP as a diagnostic clue could result in unneccessary biopsies in as many as 50% of Black patients with benign plantar hyperpigmentation.2 Furthermore, biopsies of the plantar surface can be painful and cause pain while walking.

It has been suggested that PRP seen on dermoscopy in benign hyperpigmentation such as ethnic melanosis and nevi may preserve the acrosyringia (eccrine gland openings on the ridge), whereas PRP in melanoma may obliterate the acrosyringia.13 This observation is based on case reports only and needs further study. However, if validated, it could be a useful diagnostic clue.

 

 

Worth noting

In a retrospective cohort study of skin cancer in Black individuals (n=165) at a New York City–based cancer center from 2000 to 2020, 68% of patients were diagnosed with melanomas—80% were the acral subtype and 75% displayed a PRP. However, the surrounding uninvolved background skin, which was visible in most cases, also demonstrated a PRP.14 Because of the high morbidity and mortality rates of acral melanoma, clinicians should biopsy or immediately refer patients with concerning plantar hyperpigmentation to a dermatologist.

 

Health disparity highlight

The mortality rate for acral melanoma in Black patients is disproportionately high for the following reasons15,16:

• Patients and health care providers do not expect to see melanoma in Black patients (it truly is rare!), so screening and education on sun protection are limited.

• Benign ethnic melanosis makes it more difficult to distinguish between early acral melanoma and benign skin changes.

• Black patients and other US patient populations with skin of color may be less likely to have health insurance, which contributes to inequities in access to health care. As of 2022, the uninsured rates for nonelderly American Indian and Alaska Native, Hispanic, Native Hawaiian and Other Pacific Islander, Black, and White individuals were 19.1%, 18.0%, 12.7%, 10.0%, and 6.6%, respectively.17

Multi-institutional registries could improve understanding of acral melanoma in Black patients.4 More studies are needed to help differentiate between the dermoscopic finding of PRP in benign ethnic melanosis vs malignant melanoma.

References

1. Huang K, Fan J, Misra S. Acral lentiginous melanoma: incidence and survival in the United States, 2006-2015: an analysis of the SEER registry. J Surg Res. 2020;251:329-339. doi:10.1016/j.jss.2020.02.010

2. Coleman WP, Gately LE, Krementz AB, et al. Nevi, lentigines, and melanomas in blacks. Arch Dermatol. 1980;116:548-551.

3. Centers for Disease Control and Prevention. Melanoma Incidence and Mortality, United States: 2012-2016. USCS Data Brief, no. 9. Centers for Disease Control and Prevention, US Department of Health and Human Services; 2019. https://www.cdc.gov/cancer/uscs/about/data-briefs/no9-melanoma-incidence-mortality-UnitedStates-2012-2016.htm

4. Wix SN, Brown AB, Heberton M, et al. Clinical features and outcomes of black patients with melanoma. JAMA Dermatol. 2024;160:328-333. doi:10.1001/jamadermatol.2023.5789

5. Saida T, Koga H. Dermoscopic patterns of acral melanocytic nevi: their variations, changes, and significance. Arch Dermatol. 2007;143:1423-1426. doi:10.1001/archderm.143.11.1423

6. Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol. 2011;38:25-34. doi:10.1111/j.1346-8138.2010.01174.x

7. Saida T, Miyazaki A, Oguchi S. Significance of dermoscopic patterns in detecting malignant melanoma on acral volar skin: results of a multicenter study in Japan. Arch Dermatol. 2004;140:1233-1238. doi:10.1001/archderm.140.10.1233

8. Saida T, Koga H, Uhara H. Dermoscopy for acral melanocytic lesions: revision of the 3-step algorithm and refined definition of the regular and irregular fibrillar pattern. Dermatol Pract Concept. 2022;12:e2022123. doi:10.5826/dpc.1203a123

9. Heath CR, Usatine RP. Melanoma. Cutis. 2022;109:284-285. doi:10.12788/cutis.0513.

10. Dinnes J, Deeks JJ, Chuchu N, et al; Cochrane Skin Cancer Diagnostic Test Accuracy Group. Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults. Cochrane Database Syst Rev. 2018; 12:CD011901. doi:10.1002/14651858.CD011901.pub2

11. Vestergaard ME, Macaskill P, Holt PE, et al. Dermoscopy compared with naked-eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol. 2008;159:669-676. doi:10.1111/j.1365-2133.2008.08713.x

12. Phan A, Dalle S, Marcilly MC, et al. Benign dermoscopic parallel ridge pattern variants. Arch Dermatol. 2011;147:634. doi:10.1001/archdermatol.2011.47

13. Fracaroli TS, Lavorato FG, Maceira JP, et al. Parallel ridge pattern on dermoscopy: observation in non-melanoma cases. An Bras Dermatol. 2013;88:646-648. doi:10.1590/abd1806-4841.20132058

14. Manci RN, Dauscher M, Marchetti MA, et al. Features of skin cancer in black individuals: a single-institution retrospective cohort study. Dermatol Pract Concept. 2022;12:e2022075. doi:10.5826/dpc.1202a75

15. Dawes SM, Tsai S, Gittleman H, et al. Racial disparities in melanoma survival. J Am Acad Dematol. 2016;75:983-991. doi:10.1016/j.jaad.2016.06.006

16. Ingrassia JP, Stein JA, Levine A, et al. Diagnosis and management of acral pigmented lesions. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2023;49:926-931. doi:10.1097/DSS.0000000000003891

17. Hill L, Artiga S, Damico A. Health coverage by race and ethnicity, 2010-2022. Kaiser Family Foundation. Published January 11, 2024. Accessed May 9, 2024. https://www.kff.org/racial-equity-and-health-policy/issue-brief/health-coverage-by-race-and-ethnicity

References

1. Huang K, Fan J, Misra S. Acral lentiginous melanoma: incidence and survival in the United States, 2006-2015: an analysis of the SEER registry. J Surg Res. 2020;251:329-339. doi:10.1016/j.jss.2020.02.010

2. Coleman WP, Gately LE, Krementz AB, et al. Nevi, lentigines, and melanomas in blacks. Arch Dermatol. 1980;116:548-551.

3. Centers for Disease Control and Prevention. Melanoma Incidence and Mortality, United States: 2012-2016. USCS Data Brief, no. 9. Centers for Disease Control and Prevention, US Department of Health and Human Services; 2019. https://www.cdc.gov/cancer/uscs/about/data-briefs/no9-melanoma-incidence-mortality-UnitedStates-2012-2016.htm

4. Wix SN, Brown AB, Heberton M, et al. Clinical features and outcomes of black patients with melanoma. JAMA Dermatol. 2024;160:328-333. doi:10.1001/jamadermatol.2023.5789

5. Saida T, Koga H. Dermoscopic patterns of acral melanocytic nevi: their variations, changes, and significance. Arch Dermatol. 2007;143:1423-1426. doi:10.1001/archderm.143.11.1423

6. Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol. 2011;38:25-34. doi:10.1111/j.1346-8138.2010.01174.x

7. Saida T, Miyazaki A, Oguchi S. Significance of dermoscopic patterns in detecting malignant melanoma on acral volar skin: results of a multicenter study in Japan. Arch Dermatol. 2004;140:1233-1238. doi:10.1001/archderm.140.10.1233

8. Saida T, Koga H, Uhara H. Dermoscopy for acral melanocytic lesions: revision of the 3-step algorithm and refined definition of the regular and irregular fibrillar pattern. Dermatol Pract Concept. 2022;12:e2022123. doi:10.5826/dpc.1203a123

9. Heath CR, Usatine RP. Melanoma. Cutis. 2022;109:284-285. doi:10.12788/cutis.0513.

10. Dinnes J, Deeks JJ, Chuchu N, et al; Cochrane Skin Cancer Diagnostic Test Accuracy Group. Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults. Cochrane Database Syst Rev. 2018; 12:CD011901. doi:10.1002/14651858.CD011901.pub2

11. Vestergaard ME, Macaskill P, Holt PE, et al. Dermoscopy compared with naked-eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol. 2008;159:669-676. doi:10.1111/j.1365-2133.2008.08713.x

12. Phan A, Dalle S, Marcilly MC, et al. Benign dermoscopic parallel ridge pattern variants. Arch Dermatol. 2011;147:634. doi:10.1001/archdermatol.2011.47

13. Fracaroli TS, Lavorato FG, Maceira JP, et al. Parallel ridge pattern on dermoscopy: observation in non-melanoma cases. An Bras Dermatol. 2013;88:646-648. doi:10.1590/abd1806-4841.20132058

14. Manci RN, Dauscher M, Marchetti MA, et al. Features of skin cancer in black individuals: a single-institution retrospective cohort study. Dermatol Pract Concept. 2022;12:e2022075. doi:10.5826/dpc.1202a75

15. Dawes SM, Tsai S, Gittleman H, et al. Racial disparities in melanoma survival. J Am Acad Dematol. 2016;75:983-991. doi:10.1016/j.jaad.2016.06.006

16. Ingrassia JP, Stein JA, Levine A, et al. Diagnosis and management of acral pigmented lesions. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2023;49:926-931. doi:10.1097/DSS.0000000000003891

17. Hill L, Artiga S, Damico A. Health coverage by race and ethnicity, 2010-2022. Kaiser Family Foundation. Published January 11, 2024. Accessed May 9, 2024. https://www.kff.org/racial-equity-and-health-policy/issue-brief/health-coverage-by-race-and-ethnicity

Issue
Federal Practitioner - 41(6)
Issue
Federal Practitioner - 41(6)
Page Number
170-171
Page Number
170-171
Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Dx Across the Skin Color Spectrum
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media